

(19)



(11)

EP 1 583 529 B9

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

(15) Correction information:

Corrected version no 1 (W1 B1)

Corrections, see

Description Paragraph(s) 26, 47

(48) Corrigendum issued on:

04.04.2012 Bulletin 2012/14

(45) Date of publication and mention
of the grant of the patent:

09.11.2011 Bulletin 2011/45

(21) Application number: **04701752.0**

(22) Date of filing: **13.01.2004**

(51) Int Cl.:

A61K 31/421 (2006.01)

A61K 31/426 (2006.01)

C07D 277/34 (2006.01)

A61P 3/04 (2006.01)

A61P 3/08 (2006.01)

A61P 19/02 (2006.01)

A61P 29/00 (2006.01)

A61K 31/422 (2006.01)

A61K 31/427 (2006.01)

C07D 263/44 (2006.01)

A61P 3/06 (2006.01)

A61P 3/10 (2006.01)

A61P 25/00 (2006.01)

A61P 37/02 (2006.01)

(86) International application number:

PCT/US2004/000790

(87) International publication number:

WO 2004/066964 (12.08.2004 Gazette 2004/33)

(54) **AMINO ACID PHENOXY ETHERS, THEIR PREPARATION AND USES**

AMINOSÄURE-PHENOXY-ETHER, IHRE HERSTELLUNG UND VERWENDUNGEN

ETHERS DE PHENOXY D'ACIDE AMINE, LEUR PRÉPARATION ET UTILISATIONS

(84) Designated Contracting States:

**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PT RO SE SI SK TR**

Designated Extension States:

AL LT LV MK

(30) Priority: **17.01.2003 US 440772 P**

31.01.2003 US 356113

(43) Date of publication of application:

12.10.2005 Bulletin 2005/41

(73) Proprietor: **Bexel Pharmaceuticals Inc**

Union City, CA 94587 (US)

(72) Inventors:

• **NAG, Bishwajit**

Union City, CA 94587 (US)

• **NAG, Abhijeet**

Fremont, CA 94555 (US)

• **DEY, Debendranath**

Fremont, CA 94587 (US)

• **AGARWAL, Shiv, Kumar**

600 119 Chennai (IN)

(74) Representative: **Srinivasan, Ravi Chandran et al**

J.A. Kemp & Co.

14 South Square

Gray's Inn

London WC1R 5JJ (GB)

(56) References cited:

EP-A- 1 213 287

US-A- 5 441 971

US-B1- 6 730 687

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 583 529 B9

Description**Field of the invention**

[0001] The present invention relates to novel amino acid phenyl ethers for the treatment of immunological diseases, inflammation, obesity, hyperlipidemia, hypertension, neurological diseases and diabetes.

Background of the invention

[0002] The principal elements of the immune system are macrophages or antigen-presenting cells, T cells and B cells. The role of other immune cells such as NK cells, basophils, mast cells and dendritic cells are known, but their role in primary immunologic disorders is uncertain. Macrophages are important mediators of both inflammation and providing the necessary "help" for T cell stimulation and proliferation. Most importantly macrophages make IL 1, IL 12 and TNF- α all of which are potent pro-inflammatory molecules and also provide help for T cells. In addition, activation of macrophages results in the induction of enzymes, such as cyclooxygenase II (COX-2), inducible nitric oxide synthase (iNOS) and production of free radicals capable of damaging normal cells. Many factors activate macrophages, including bacterial products, superantigens and interferon gamma (IFN γ). It is believed that phosphotyrosine kinases (PTKs) and other undefined cellular kinases are involved in the activation process.

[0003] Cytokines are molecules secreted by immune cells that are important in mediating immune responses. Cytokine production may lead to the secretion of other cytokines, altered cellular function, cell division or differentiation. Inflammation is the normal response to injury or infection. However, in inflammatory diseases such as rheumatoid arthritis, pathologic inflammatory processes can lead to morbidity and mortality. The cytokine tumor necrosis factor-alpha (TNF- α) plays a central role in the inflammatory response and has been targeted as a point of intervention in inflammatory disease. TNF- α is a polypeptide hormone released by activated macrophages and other cells. At low concentrations, TNF- α participates in the protective inflammatory response by activating leukocytes and promoting their migration to extravascular sites of inflammation (Moser et al., J Clin Invest, 83:444-55, 1989). At higher concentrations, TNF- α can act as a potent pyrogen and induce the production of other pro-inflammatory cytokines (Haworth et al., Eur J Immunol, 21:2575-79, 1991; Brennan et al., Lancet, 2:244-7, 1989). TNF- α also stimulates the synthesis of acute-phase proteins. In rheumatoid arthritis, a chronic and progressive inflammatory disease affecting about 1% of the adult U.S. population, TNF- α mediates the cytokine cascade that leads to joint damage and destruction (Arend et al., Arthritis Rheum, 38: 151-60, 1995). Inhibitors of TNF- α , including soluble TNF receptors (etanercept) (Goldenberg, Clin Ther, 21:75-87, 1999) and anti-TNF- α antibody (infliximab) (Luong et al., Ann Pharmacother, 34:743-60, 2000), have recently been approved by the U.S. Food and Drug Administration (FDA) as agents for the treatment of rheumatoid arthritis.

[0004] Elevated levels of TNF- α have also been implicated in many other disorders and disease conditions, including cachexia, septic shock syndrome, osteoarthritis, inflammatory bowel disease such as Crohn's disease and ulcerative colitis etc.

[0005] Excessive production of IL-6 is implicated in several disease states, it is highly desirable to develop compounds that inhibit IL-6 secretion.

[0006] The cytokine IL-1 β also participates in the inflammatory response. It stimulates thymocyte proliferation, fibroblast growth factor activity, and the release of prostaglandin from synovial cells.

[0007] Elevated or unregulated levels of the cytokine IL-1 β have been associated with a number of inflammatory diseases and other disease states, including but not limited to adult respiratory distress syndrome, allergy, Alzheimer's disease etc.

[0008] Since overproduction of IL-1 β is associated with numerous disease conditions, it is desirable to develop compounds that inhibit the production or activity of IL-1 β .

[0009] It will be appreciated from the foregoing that, while there have been extensive prior efforts to provide compounds for inhibiting, for example, TNF- α , IL-1, IL-6, COX-2 or other agents considered responsible for immune response, inflammation or inflammatory diseases, e.g. arthritis, there still remains a need for new and improved compounds for effectively treating or inhibiting such diseases.

[0010] There appears to be a correlation of TNF- α to adipogenesis (obesity) and other metabolic disorders such as diabetes mellitus. Although, in the past two decades there has been an explosive increase in number of people diagnosed with diabetes worldwide [Amos A., McCarty, D., Zimmet, P. (1997) Diabetic Med. 14, S1-S85; King, H., Aubert, R., Herman, W. (1998) Diabetes Care, 21, 1414-1431], there has been relatively little development of new therapeutics for the treatment of diabetes and its associated conditions [Moller, D.E. (2001) Nature 414, 821-827]. Diabetes exists in two types: insulin dependent Type-I and non-Insulin dependent (insulin-resistant) Type-II. Type-II insulin-resistant diabetes mellitus accounts for 90-95% of all diabetes. This syndromic metabolic disorder currently affects more than 150 million people worldwide and is projected to grow to 300 million by year 2005 [Amos, A., McCarty, D., Zimmet, P. (1997) Diabetic Med. 14, S1-S85; Kopelman, P.G. Hitaman, G.A. (1998) Lancet, 352, SIV5]. The main force driving this increase

in incidence of type II diabetes is an increase in obesity, the single most important contribution to the pathogenesis of type II diabetes [Kopelman, P.G., Hitaman, G.A. (1998) Lancet, 352, SIV5].

[0011] At present, therapy for type II diabetes relies mainly on several approaches intended to reduce the hyperglycemia itself. These are: sulfonylureas and related insulin secretogens that are known to release more insulin from pancreatic β cells; metformin, that acts to reduce hepatic glucose production; peroxisome proliferator-activated receptor (PPAR) agonists that enhances insulin action; α -glucosidase inhibitors that slow down absorption of glucose from the gut; and insulin itself, that suppresses glucose production and augments glucose utilization (summarized in table I below). All of these therapies have limited efficacy, limited tolerability and significant mechanism-based side effects. Of particular concern is the tendency for most treatment to enhance body weight gain. Several current treatments for type II diabetes are associated with episodes of hypoglycemia, and few of the available therapies adequately address underlying defects such as obesity and a phenomenon known as insulin resistance. Among these oral medications, sulfonylureas represent the oldest and widely used form of treatment. Many patients who respond to sulfonylureas initially become refractory to the treatment over time (secondary failure). Besides glucose level and obesity, type II diabetes is now linked with high level of triglycerides and cholesterol. Therefore, there is a need for new classes of drugs addressing the underlying issue of metabolic defects (increasingly known as Syndrome-X) such as obesity, hyperglycemia and hyperlipidemic conditions to address type II diabetes and its associated condition.


Table 1: Current Therapeutic agents for Type II Diabetes

Drug class	Delivery	Molecular	Target	Site of Action	Adverse Events
Insulin	Intramuscular		Insulin receptor	Liver, Muscle, Fat	Weight gain
Hypoglycemia					
Sulfonylureas (glibenclamide) Hypoglycemia (repaglinide) (nateglinide)	Oral		SU receptors K ⁺ /ATPchannel	Pancreatic β cells	Weight gain
Metformin (biguanides)	Oral		Unknown	Liver (muscle)	GI disturbance Lactic acidosis
α - Glucosidase Inhibitors (Acarbose)	Oral		α - Glucosidase	Intestine	disturbance
PPAR- agonist (Rosiglitazone) (Pioglitazone)	Oral		PPAR- gamma	Fat, Muscle, Liver	Weight gain Anaemia Oedema

[0012] Additionally, US 5441971 discloses thiazolidinedione derivatives for the treatment of diabetes.

Summary of the invention

[0013] The present invention relates to a compound formula (I)



its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts, its pharmaceutically ac-

ceptable solvates, wherein ---- represents an optional double bond; Y represents oxygen, sulfur or NR, wherein R represents hydrogen or alkyl; Z represents oxygen or sulfur; R₁, R₂, R₃ and R₄ may be same or different and independently represent hydrogen, halogen, hydroxy, nitro, cyano, formyl, amino, alkyl, or alkoxy; A represents a bond or substituted or unsubstituted aryl, heterocyclyl or heteroaryl ring; X represents an alpha amino carboxylic acid or alpha amino carboxylic acid derivative in which the amino group is carboxylated or the carboxylic acid group is esterified or is an amide, wherein X is bonded to A or Y through its alpha side chain.

[0014] The present invention also relates to a process for the preparation of the above said novel compounds, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, novel intermediates and pharmaceutical compositions containing them. Tautomeric forms are isomeric forms which exists in a state of equilibrium capable of reacting according to either form. Stereoisomers include configurational isomers, such as cis- and trans-double bonds, as well as optically active isomers having different spatial arrangements of their atoms. Polymorphs are molecules which can crystallize in two or more forms. Solvates are molecular or ionic complexes of molecules or ions of solvent with those of a solute. An alpha-amino carboxylic acid includes, but is not limited to, naturally-occurring amino acids. The alpha side chain is a group, including hydrogen, covalently bonded to the alpha carbon of an alpha-amino carboxylic acid. Derivatives include compounds resulting from routine functionalizing of atoms, such as, derivatives found by protecting amino or carboxyl groups by carboxylation or esterification, respectively.

[0015] The compounds of the present invention are effective in lowering blood glucose, serum insulin, free fatty acids, cholesterol and triglyceride levels and are useful in the treatment and / or prophylaxis of diabetes. The compounds of the present invention are effective in treatment of obesity, inflammation, autoimmune diseases such as such as multiple sclerosis and rheumatoid arthritis. Surprisingly, these compounds increase the leptin level and have no liver toxicity.

[0016] Furthermore, the compounds of the present invention are useful for the treatment of disorders associated with insulin resistance, such as polycystic ovary syndrome, as well as hyperlipidemia, coronary artery disease and peripheral vascular disease, and for the treatment of inflammation and immunological diseases, particularly those mediated by cytokines such as TNF- α , IL-1, IL-6, IL-1 β and cyclooxygenase such as COX-2.

Brief Description of figures

[0017]

Figure 1 shows that the compounds in Example 1 lower pro-inflammatory cytokines in human macrophage cells.
 Figure 2 shows efficacy of compound 2 in Example 1 in an animal model of inflammation.
 Figure 3 shows efficacy of compounds 1 and 2 in Example 1 in an animal model of autoimmunity.
 Figure 4 represents schematic illustration of various cytokines and their role in management of a number of inflammatory and autoimmune diseases.
 Figure 5 is a schematic illustration of how TNF α is linked to various metabolic disorders besides its inflammatory and autoimmune properties.
 Figure 6 shows the blood glucose lowering effect of compound in Example 1 in ob/ob and db/db mice.
 Figure 7 shows the effect of compounds 1 and 2 in Example 1 in weight gain reduction in an animal model of obesity.
 Figure 8 shows the effect of compound 2 in Example 1 an insulin sensitizing and lipid lowering activity.
 Figure 9 shows the effect of lipid accumulation in human preadipocytes when treated with various dosages of a compound of the invention compared to rosiglitazone.

Detailed description of the invention

[0018] In an embodiment of the present invention, the groups represented by R₁, R₂, R₃ and R₄ are selected from hydrogen, halogen such as fluorine, chlorine, bromine or iodine; hydroxy, nitro, cyano, formyl, amino, linear or branched, substituted or unsubstituted (C₁-C₁₂)alkyl group such as methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, t-butyl, pentyl, hexyl, octal and nonyl; substituted or unsubstituted (C₁-C₁₂)alkoxy group such as methoxy, ethoxy, propoxy and butoxy.

[0019] In an embodiment of the present invention; the group represented by A is selected from aryl such as phenyl and naphthyl; heteroaryl ring such as pyridyl, pyrrolyl, thiazolyl, indolyl, imidazolyl and furyl; heterocyclyl ring such as piperzine, morpholine, piperidine and pyrrolidine. The group A may be mono, di or tri substituted and the substituents are selected from halogen, hydroxy, nitro, cyano, formyl, amino, alkyl, haloalkyl, alkoxy, and haloalkoxy.


[0020] In an embodiment of the present invention, the amino acid and side chain represented by X, X-A or X-A-Y is selected from alanine, glycine, arginine, asparagine, cysteine, glutamic acid, glutamine, histidine, isoleucine, leucine, lysine, methionine, ornithine, proline, serine, threonine, tryptophan and tyrosine, which may be substituted or unsubstituted and their derivatives such as ester and amides of carboxylic acid. The preferred substituents are selected from halogen, alkyl, alkoxy, aryl, heteroaryl and amino.

[0021] The amino acid X-A-Y preferably represents substituted or unsubstituted arginine, asparagine, cysteine, glutamine, histidine, lysine, methionine, ornithine, proline, serine, threonine, tryptophan, tyrosine and their derivatives in which the amino group is carboxylated or the carboxylic acid group is esterified or is an amide. The group X-A also preferably represents alanine, glycine, isoleucine, leucine and their derivatives in which the amino group is carboxylated or the carboxylic acid group is esterified or is an amide. In another embodiment A represents a substituted or unsubstituted alkyl, heterocyclyl or heteroaryl ring.

[0022] In another embodiment, Z is sulfur and Y is oxygen. Preferably, R, through R₄ are hydrogen.


[0023] Pharmaceutically acceptable salts forming part of this invention include base addition salts such as alkali metal salts like Li, Na, and K salts, alkaline earth metal salts like Ca and Mg salts, salts of organic bases such as lysine, arginine, guanidine, diethanolamine and choline, ammonium or substituted ammonium salts. Salts may include acid addition salts which are, sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates and ketoglutarates. Pharmaceutically acceptable solvates may be hydrates or comprising other solvents of crystallization such as alcohols.

[0024] Preferably the present invention relates to novel amino acid phenyl ethers of formula (I)



their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, wherein -- represents an optional double bond; Y represents oxygen, sulfur or NR, wherein R represents hydrogen or alkyl; Z represents oxygen or sulfur; R₁, R₂, R₃ and R₄ may be same or different and independently represent hydrogen, halogen, hydroxy, nitro, cyano, formyl, amino, alkyl, or alkoxy; A represents substituted or unsubstituted aryl; X represents an alpha amino carboxylic acid or a derivative thereof in which the amino group is carboxylated or the carboxylic acid group is esterified or is an amide, wherein X is bonded to A or Y through its alpha side chain.

[0025] More preferably, the present invention relates to novel amino acid phenyl ethers of formula (I)




their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, wherein --- represents optional double bond; Y represents oxygen, sulfur or NR, wherein R represents hydrogen or alkyl; Z represents oxygen or sulfur; R₁, R₂, R₃ and R₄ may be same or different and independently represent hydrogen, halogen, hydroxy, nitro, cyano, formyl, amino, alkyl, or alkoxy; A represents, substituted or unsubstituted phenyl; X represents alanine or a derivative thereof in which the amino group is carboxylated or the carboxylic acid group is esterified or is an amide, wherein X is bonded to A or Y through its alpha methyl group.

[0026] Particularly useful compounds according to the invention include:

- 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)benzylidene]thiazolidin-2,4-dione or its salts;
- 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)benzylidene]thiazolidin-2,4-dione or its salts;
- 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)benzyl]thiazolidin-2,4-dione or its salts;
- 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)benzyl]thiazolidin-2,4-dione or its salts;
- 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)benzylidene]oxazolidin-2,4-dione or its salts;
- 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)benzylidene]oxazolidin-2,4-dione or its salts;
- 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)benzyl]oxazolidin-2,4-dione or its salts;
- 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)benzyl]oxazolidin-2,4-dione or its salts;































5-[4-(4-(2-t-butoxycarbonylamino-2-carboxyethyl)phenoxy)benzyl]thiazolidin-2,4-dione or its salts;
 5-[4-(4-(2-t-butoxycarbonylamino-2-carboxyethyl)phenoxy) benzilidene]oxazolidin-2,4-dione or its salts and
 5-[4-(4-(2-t-butoxycarbonylamino-2-carboxyethyl)phenoxy)benzyl]oxazolidin-2,4-dione or its salts.



R₁ is H

Compd No.	X	A	Y	R ₂ , R ₃	R ₄	Z
1			O	H, H	H	S
2			O	H, H	H	S
3			O	H, H	2H	S
4			O	H, H	2H	S
5			O	H, H	H	O
6			O	H, H	H	O
7			O	H, H	2H	O
8			O	H, H	2H	O
9			O	2-F, 6-F	H	O
10			O	2-F, 6-F	H	O
11			O	2-F, 6-F	2H	O

(continued)

Compd No.	X	A	Y	R ₂ , R ₃	R ₄	Z
12			O	2-F, 6-F	2H	O
13			O	2-F, 6-F	H	S
14			O	2-F, 6-F	H	S
15			O	2-F, 6-F	2H	S
16			O	2-F, 6-F	2H	S
17			O	2-F, 3-F	H	S
18			O	2-F, 3-F	H	S
19			O	2-F, 3-F	2H	S
20			O	2-F, 3-F	2H	S
21			O	2-F, 3-F	H	O
22			O	2-F, 3-F	H	O
23			O	2-F, 3-F	2H	O
24			O	2-F, 3-F	2H	O
25			O	3-Me	H	O
26			O	3-Me	H	O

(continued)

Compd No.	X	A	Y	R ₂ , R ₃	R ₄	Z
27			O	3-Me	2H	O
28			O	3-Me	2H	O
29			O	3-Me	H	S
30			O	3-Me	H	S
31			O	3-Me	2H	S
32			O	3-Me	2H	S
33			O	3-NO ₂	H	S
34			O	3-NO ₂	H	S
35			O	3-NO ₂	2H	S
36			O	3-NO ₂	2H	S
37			O	3-NO ₂	H	O
38			O	3-NO ₂	H	O
39			O	3-NO ₂	2H	O
40			O	3-NO ₂	2H	O



























(continued)

Compd No.	X	A	Y	R ₂ , R ₃	R ₄	Z
41			O	3-NH ₂	H	S
42			O	3-NH ₂	H	S
43			O	3-NH ₂	2H	S
44			O	3-NH ₂	2H	S
45			O	3-NH ₂	H	O
46			O	3-NH ₂	H	O
47			O	3-NH ₂	2H	O
48			O	3-NH ₂	2H	O
49			O	2-F	H	S
50			O	2-F	H	S
51			O	2-F	2H	S
52			O	2-F	2H	S
53			O	2-F	H	O
54			O	2-F	H	O
55			O	2-F	2H	O




















(continued)

Compd No.	X	A	Y	R ₂ , R ₃	R ₄	Z
56			O	2-F	2H	O
57			O	3-F	H	S
58			O	3-F	H	S
59			O	3-F	2H	S
60			O	3-F	2H	S
61			O	3-F	H	O
62			O	3-F	H	O
63			O	3-F	2H	O
64			O	3-F	2H	O
65			O	2-CF ₃	H	S
66			O	2-CF ₃	H	S
67			O	2-CF ₃	2H	S
68			O	2-CF ₃	2H	S
69			O	2-CF ₃	H	O























(continued)

Compd No.	X	A	Y	R ₂ , R ₃	R ₄	Z
70			O	2-CF ₃	H	O
71			O	2-CF ₃	2H	O
72			O	2-CF ₃	2H	O
73			O	3-CF ₃	H	S
74			O	3-CF ₃	H	S
75			O	3-CF ₃	2H	S
76			O	3-CF ₃	2H	S
77			O	3-CF ₃	H	O
78			O	3-CF ₃	H	O
79			O	3-CF ₃	2H	O
80			O	3-CF ₃	2H	O
81			O	H, H	H	O
82			O	H, H	H	O





















(continued)

Compd No.	X	A	Y	R ₂ , R ₃	R ₄	Z
83			O	H, H	2H	O
84			O	H, H	2H	O
85			O	H, H	H	S
86			O	H, H	H	S
87			O	H, H	2H	S
88			O	H, H	2H	S
89			O	H, H	H	S
90			O	H, H	H	S
91			O	H, H	2H	S
92			O	H, H	2H	S





















(continued)

Compd No.	X	A	Y	R ₂ , R ₃	R ₄	Z
93			O	H, H	H	O
94			O	H, H	H	O
95			O	H, H	2H	O
96			O	H, H	2H	O
97			O	H, H	H	O
98			O	H, H	H	O
99			O	H, H	2H	O
100			O	H, H	2H	O
101			O	H, H	H	S
102			O	H, H	H	S
103			O	H, H	2H	S

























(continued)

Compd No.	X	A	Y	R ₂ , R ₃	R ₄	Z
104			O	H, H	2H	S
105			O	H, H	H	O
106			O	H, H	H	O
107			O	H, H	2H	O
108			O	H, H	2H	O
109			O	H, H	H	S
110			O	H, H	H	S
111			O	H, H	2H	S
112			O	H, H	2H	S
113			O	H, H	H	S

(continued)

Compd No.	X	A	Y	R ₂ , R ₃	R ₄	Z
114			O	H, H	H	S
115			O	H, H	2H	S
116			O	H, H	2H	S
117			O	H, H	H	O
118			O	H, H	H	O
119			O	H, H	2H	O
120			O	H, H	2H	O
121			O	H, H	H	S
122			O	H, H	H	S
123			O	H, H	2H	S























(continued)

Compd No.	X	A	Y	R ₂ , R ₃	R ₄	Z
124			O	H, H	2H	S
125			O	H, H	H	O
126			O	H, H	H	O
127			O	H, H	2H	O
128			O	H, H	2H	O
129			O	H, H	H	S
130			O	H, H	H	S
131			O	H, H	2H	S
132			O	H, H	2H	S
133			O	H, H	H	O
134			O	H, H	H	O
135			O	H, H	2H	O





















(continued)

Compd No.	X	A	Y	R ₂ , R ₃	R ₄	Z
136			O	H, H	2H	O
137			O	H, H	H	S
138			O	H, H	H	S
139			O	H, H	2H	S
140			O	H, H	2H	S
141			O	H, H	H	O
142			O	H, H	H	O
143			O	H, H	2H	O
144			O	H, H	2H	O
145			O	H, H	H	S
146			O	H, H	H	S
147			O	H, H	2H	S

(continued)


Compd No.	X	A	Y	R ₂ , R ₃	R ₄	Z
148			O	H, H	2H	S
149			O	H, H	H	O
150			O	H, H	H	O
151			O	H, H	2H	O
152			O	H, H	2H	O
153			O	H, H	H	S
154			O	H, H	H	S
155			O	H, H	2H	S
156			O	H, H	2H	S
157			O	H, H	H	O
158			O	H, H	H	O

(continued)

Compd No.	X	A	Y	R ₂ , R ₃	R ₄	Z
159			O	H, H	2H	O
160			O	H, H	2H	O
161			O	H, H	H	S
162			O	H, H	2H	S
163			O	H, H	H	O
164			O	H, H	2H	O
165			O	H, H	H	S
166			O	H, H	2H	S
167			O	H, H	H	O
168			O	H, H	2H	O

[0027] Preferred salts for the list of compounds above are hydrochloride, hydrobromide, sodium, potassium or magnesium.

[0028] According to another feature of the present invention, there is provided a process for the preparation of compounds of formula (I), wherein --- represents a bond and all other symbols are as defined earlier, as shown in scheme- I

**Scheme-I**


[0029] The reaction of compound of formula (IIIa) wherein X_1 represents a protected alpha amino carboxylic acid group and all other symbols are as defined earlier with the compound of formula (IIIb) wherein L represents a nucleophilic aromatic substitution leaving group, and all other symbols are as defined earlier to produce a compound of formula (IIIc) may be carried out in the presence of solvents such as THF, DMF, DMSO and DME or mixtures of solvents may be used. The reaction may be carried out in an inert atmosphere which may be maintained by using inert gases such as N_2 , Ar or He. The reaction may be effected in the presence of a base such as K_2CO_3 , Na_2CO_3 , NaH or mixtures thereof. The reaction temperature may range from 20 °C to 150 °C, preferably at a temperature in the range of 30 °C to 100 °C. The duration of the reaction may range from 1 to 24 hours, preferably from 2 to 6 hours.

[0030] The conventional protecting groups used are those that can be easily removed and are selected from t-Boc, CBz, F-moc, etc.

[0031] The reaction of the compound of the general formula (IIIc) with 2,4-thiazolidinedione or 2,4-oxazolidinedione to yield a compound of formula (IIId) may be carried out neat in the presence of sodium acetate or in the presence of a solvent such as benzene, toluene, methoxyethanol or mixtures thereof. The reaction temperature may range from 80 °C to 180 °C, when the reaction is carried out neat in the presence of sodium acetate. Suitable catalyst such as piperidinium acetate or benzoate, sodium acetate or mixtures of catalysts may also be employed. Sodium acetate can be used in the presence of solvent, but it is preferred that sodium acetate is used neat. The water produced in the reaction may be removed, for example, by using Dean Stark water separator or by using water absorbing agents like molecular sieves.

[0032] The deprotection of amino acid group of formula (IIId) to yield compound of formula (I) may be carried out using acids such as HCl, sulfuric acid, acetic acid in the presence of solvents such as DCM, ethyl acetate and water or mixture thereof at a temperature in the range of -10 °C to 50 °C.

[0033] In another embodiment of the present invention, the compounds of general formula (I) wherein Z represents sulfur, --- represents no bond can be prepared by reacting the compound of formula (IIIe)




wherein J is halogen atom, like chlorine, bromine or iodine and R_5 is a lower alkyl group with thiourea followed by treatment with an acid.

[0034] The reaction of compound of general formula (IIIe) with thiourea is carried out in the presence of alcoholic solvent such as methanol, ethanol, propanol, isobutanol, 2-methoxybutanol, etc or DMSO or sulfolane. The reaction may be conducted at a temperature in the range between 20 °C and the reflux temperature of the solvent used. Bases such as NaOAc, KOAc, NaOMe, NaOEt etc. can be used.

[0035] In yet another embodiment of the present invention, the compounds of the general formula (I) wherein --- represents a bond and all other symbols are as defined earlier can also be prepared by reacting a compound of formula



wherein L is a nucleophilic leaving such as halogen atom, like chlorine, bromine or iodine; methanesulfonate, trifluoromethanesulfonate and p-toluenesulfonate with a compound of the formula (IIIg).




[0036] The reaction of compound of general formula (III f) with a compound of general formula (IIIg) to produce a compound of general formula (I) may be carried out in the presence of solvents such as THF, DMF, DMSO and DME or mixtures thereof. The reaction may be carried out in an inert atmosphere which may be maintained by using inert gases such as N₂, Ar or He. The reaction may be effected in the presence of a base such as alkalis like sodium hydroxide or potassium hydroxide; alkali metal carbonates like sodium carbonate or potassium carbonate; alkali metal hydrides such as sodium hydrides; organometallic bases like n-butyl lithium; alkali metal amides like sodamide, or mixtures thereof. Multiple solvents and bases can be used. The amount of base may range from 1 to 5 equivalents, preferably 1 to 3 equivalents. The reaction temperature may be in the range of 0 °C to 120 °C, preferably at a temperature in the range of 20 °C to 100 °C. The duration of the reaction may range from 0.5 to 24 hours, preferably from 0.5 to 6 hrs.

[0037] In yet another embodiment of the present invention, the compounds of the general formula (I) wherein --- represents a bond and all other symbols are as defined earlier can also be prepared by reacting a compound of formula



where A and X are as defined earlier with a compound of the formula (IIIg).




[0038] The reaction of compound of general formula (III h) with a compound of general formula (IIIg) to produce a compound of general formula (I) may be carried out in the presence of solvents such as THF, DMF, DMSO and DME or mixtures thereof. The reaction may be carried out in an inert atmosphere which may be maintained by using inert gases such as N₂, Ar or He. The reaction may be effected in the presence of a base such as alkalis like sodium hydroxide or potassium hydroxide; alkali metal carbonates like sodium carbonate or potassium carbonate; alkali metal hydrides such as sodium hydride; organometallic bases like n-butyl lithium; alkali metal amides like sodamide, or mixtures thereof. Multiple solvents and bases can be used. The amount of base may range from 1 to 5 equivalents, preferably 1 to 3 equivalents. The reaction temperature may be in the range of 0 °C to 120 °C, preferably at a temperature in the range of 20 °C to 100 °C. The duration of the reaction may range from 0.5 to 24 hours, preferably from 0.5 to 6 hrs.

[0039] In another embodiment of the present invention, there is provided a process for the preparation of compounds of formula (I), wherein --- represents no bond by reducing compounds of formula (I) wherein --- represents a bond and all other symbols are as defined earlier. The reduction may be carried out in the presence of gaseous hydrogen and a catalyst such as Pd/C, Rh/C, Pt/C and Raney Nickel. Mixtures of catalysts may be used. The reaction may be conducted in the presence of solvents such as dioxane, acetic acid and ethyl acetate. Mixtures of solvents may be used. A pressure

between atmospheric pressure to 100 psi may be employed. The catalyst may be 5-10% Pd/C and the amount of catalyst used may range from 50-300% w/w. The reaction may also be carried out by employing metal solvent reduction such as magnesium in methanol or sodium amalgam in methanol. The reaction may also be carried out with alkali metal borohydrides such as LiBH_4 , NaBH_4 and KBH_4 in the presence of cobalt salt such as CoCl_2 and ligands, preferably bidentated ligands such as 2,2'-bipyridyl, 1,10-phenanthroline and bisoximes.


[0040] In yet another embodiment of the present invention, there is provided an intermediate of formula (IIIc)



their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, wherein

Y represents oxygen, sulfur or NR, wherein R represents hydrogen or alkyl; R_1 , R_2 , R_3 and R_4 may be same or different and independently represent hydrogen, halogen, hydroxy, nitro, cyano, formyl, amino, alkyl, or alkoxy; A represents substituted or unsubstituted aryl; X represents an alpha amino carboxylic acid or a derivative thereof in which the amino group is carboxylated or the carboxylic acid group is esterified or is an amide, wherein X is bonded to A or Y through its alpha side chain.

[0041] In yet another embodiment of the present invention, there is provided an intermediate of formula (IIIe)



their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, wherein Y represents oxygen, sulfur or NR, wherein R represents hydrogen or alkyl; R_1 , R_2 , R_3 and R_4 may be same or different and independently represent hydrogen, halogen, hydroxy, nitro, cyano, formyl, amino, alkyl, or alkoxy; A represents substituted or unsubstituted aryl; X represents an alpha amino carboxylic acid or a derivative thereof in which the amino group is carboxylated or the carboxylic acid group is esterified or is an amide, wherein X is bonded to A or Y through its alpha side chain; J represents halogen atom and R_5 represents lower alkyl group.

[0042] It has been surprisingly found that, unlike other thiazolidine-compounds (TZD molecules), compounds of the invention exhibit no adipocyte differentiation. It is also surprising that administration reduces body weight gain. Finally, compounds of the invention appear to have no affinity for PPAR-g. These three features of the compounds are different from known TZD molecules, which typically have adipocyte differentiation activity, increase weight gain, and are PPAR-g agonists. Furthermore, compounds of the invention have anti-inflammation properties. For example, the compounds inhibit $\text{TNF}\alpha$, IL-6 and IL1 β .

[0043] The compounds according to the present invention may be combined with a physiologically acceptable vehicle in a pharmaceutical composition. The particularly preferred form of composition is an orally administrated capsule or solution in which the compound is delivered in water, saline, a phosphate buffer, or lyophilized powder in a form of tablets or capsules which also includes various fillers and binders. The effective dosages of compound in a composition will be selected by those of ordinary skill in the art and may be empirically determined.

[0044] The compounds of the present invention are useful for the treatment of inflammation, autoimmune diseases such as multiple sclerosis, IBD, obesity, neurological diseases, hypertension, and diseases such as diabetes characterized by the presence of elevated blood glucose levels, that is hyperglycemic disorders such as diabetes mellitus, including both Type I and Type II diabetes as well as other hyperglycemic related disorders such as hyperlipidemia and kidney related disorders

[0045] By "treatment," it is meant that the compound is administered at least to reduce inflammation, hypertension, obesity, blood lipid levels, blood glucose levels or symptoms associated with autoimmune or neurological disease or disorder from which the patient is suffering. The compound is administered in an amount sufficient, for example, to reduce blood glucose level to an acceptable range, wherein an acceptable range means $\pm 10\%$, usually $\pm 8\%$ and usually $\pm 5\%$ of the normal average blood glucose level for the subject. A variety of subjects may be treated with the


compounds such as livestock, valuable or rare animals, pets, as well as humans. The compounds may be administered to the subject using a convenient administration technique, including intravenous, intradermal, intramuscular, subcutaneous and oral administration. However, the oral route of administration is particularly preferred. The dosage delivered to the host will necessarily depend upon the route by which the compound is delivered, but generally ranges from 5 to 500 mg/70 kg human body weight.

[0046] The invention is explained in detail in the examples given below.

Example 1

Preparation of 5-[4-(4-(2-amino-2-methoxycarbonyl)phenoxy)benzyl]-thiazolidin-2,4-dione hydrochloride salt

[0047]



Step (i)

Preparation of methyl-2-[(t-butoxycarbonyl)amino]-3-[(4-formylphenoxy) phenyl]propanoate

[0048] To a suspension of fresh sodium hydride (0.813 g, 33.9 mmol) in dry DMF (20 ml) under nitrogen atmosphere was added the solution of methyl-2-[(t-butoxycarbonyl)amino]-3-(4-hydroxyphenyl)propanoate (10 g, 33.9 mmol) in DMF (20 ml) slowly. The mixture was stirred for 15 minutes. 4-Fluorobenzaldehyde (4.20 g, 33.9 mmol) was added and the mixture was heated to 80 °C. After completion of the reaction, the solvent was removed by high vacuum and the mixture was quenched with addition of saturated aqueous ammonium chloride. The mixture was extracted with ethyl acetate (3 x 50 ml). After washing with brine and dried on anhydrous sodium sulfate, the solvent was evaporated and the product was purified with flash column from eluent of hexanes: ethyl ether; 12/30 to 12/ 22 to afford the title compound as an oil (yield 11.5 g, 85.0 %).

¹H NMR (CDCl₃, 360 M Hz.): δ 9.92 (s, 1H), 7.83 (d, 2H), 7.19 (d, 2H), 7.05 (d, 2H), 7.03(d, 2H), 4.60(t, 1H), 3.72(s, 3H), 3.09(d, 2H), 1.42(s, 9H). The structure was confirmed by Mass Spec. Calculated (M+1) 400.4; Measured 400.3.

Step (ii)

Preparation of 5-[4-(4-(2-t-butoxycarbonylamino-2-methoxycarbonyl) phenoxy)benzilidene]thiazolidin-2,4-dione

[0049] To a solution of methyl-2-[(t-butoxycarbonyl)amino]-3-[(4-formylphenoxy) phenyl]propanoate obtained in step (i) above in anhydrous toluene (10 g, 25 mmol), 2,4-thiazolidinedione (3.53 g, 30 mmol) was added followed by benzoic acid (0.46 g, 3.75 mmol) and piperidine (0.28 g, 3.25 mmol). The solution was heated to reflux at 145-155 °C with continuous removal of water using Dean-Stark apparatus for 5 hr. The solution was cooled to RT and the yellow solid was precipitated to afford the title compound (yield 11.9 g, 96%, purity 96.5 % by HPLC, mp : 160-164 °C).

¹H NMR (CDCl₃, 360 M Hz.): 7.82(s, 1H), 7.47(d, 2H); 7.05(d, 2H), 7.00(d, 2H); 6.75(d, 2H) 5.18(m, 1H), 4.54(M, 1H), 3.71(s, 3H); 3.02(m, 2H), 3.00(m, 2H). 1.42(s, 9H). The structure was confirmed by Mass Spec. Calculated (M+1) 498.5; Measured 498.5.

Step (iii)

Preparation 5-[4-(4-(2-amino-2-methoxycarbonyl)phenoxy)benzilidene]thiazolidin-2,4-dione

[0050] A solution of 5-[4-(4-(2-t-butoxycarbonylamino-2-methoxycarbonyl) phenoxy)benzilidene]thiazolidin-2,4-dione (2 g, 4.0 mmol) in DCM (100 ml) at 0 °C was bubbled with HCl gas. After stirring for 1 hour, the yellow precipitate was filtered and 1.7 g (3.9 mmol) of HCl-Tyr (C₆H₄-CH=TD27-OMe) was collected with 97.5% yield, mp : 187-190 °C. The HPLC purity of product was 94.5%. Compound

¹H NMR (D₂O, 360 M Hz.): 7.46(s, NH, 1H); 7.24(d, 2H); 7.16(d, 2H); 6.94(d, 2H); 6.78(d, 2H); 4.80 (s, NH₃, 3H); 4.40

(m C α -H, 1H); 3.80(s, OMe). The structure was confirmed by Mass Spec. Calculated (M+1) 501.5 ; Measured 501.5.

Step (iv)

Preparation of 5-[4-(4-(2-amino-2-methoxycarbonyl) ethyl) phenoxy]benzyl]thiazolidin-2,4-dione

[0051] To a solution of 5-[4-(4-(2-amino-2-methoxycarbonyl) ethyl) phenoxy]benzyliden]thiazolidin-2,4-dione (0.7 g, 1.6 mmol) in methanol (20 ml) dry Pd/C (0.15 g) was added. After hydrogenating at 60 psi at 40 °C over night, the solution was filtered with Celite and evaporated under reduced pressure to yield quantitatively the title compound. This compound

did not show melting in DSC but changes to black colour, in capillary and shrinks at 97-133 °C. Compound 2.
[0052] The pharmaceutically acceptable salts may be prepared by reacting the compound of formula (I) with 1 to 4 equivalents of a base such as sodium hydroxide, sodium methoxide, sodium hydride, potassium t-butoxide, calcium hydroxide and magnesium hydroxide, in solvents like either, THF, methanol, t-butanol, dioxane, isopropanol, ethanol etc. Mixtures of solvents may be used. Organic bases like lysine, arginine, diethanolamine, choline, guanidine and their derivatives etc. may also be used. Alternatively, acid addition salts are prepared by treatment with acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, p-toluenesulfonic acid, methanesulfonic acid, acetic acid, citric acid, maleic acid, salicylic acid, hydroxynaphthoic acid, ascorbic acid, palmitic acid, succinic acid, benzoic acid, benzene sulfonic acid and tartaric acid in solvents like ethyl acetate, ether, alcohols, acetone, THF, dioxane etc. Mixture of solvents may also be used.

[0053] The present invention also provides a pharmaceutical composition, containing once or more of the compounds of the general formula (I) as defined above, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates in combination with the usual pharmaceutically employed carriers and diluents.

[0054] The pharmaceutical composition may be in the forms normally employed, such as tablets, capsules, powders, syrups, solutions and suspensions, may contain flavourants, sweeteners etc. in suitable solid or liquid carriers or diluents, or in suitable sterile media to form injectable solutions or suspensions. Such compositions typically contain from 1 to 25%, preferably 1 to 15% by weight of active compound, the remainder of the composition being pharmaceutically acceptable carriers, diluents, excipients or solvents.

[0055] Suitable pharmaceutically acceptable carriers include solid fillers or diluents and sterile aqueous or organic solutions. The active compound will be present in such pharmaceutical compositions in the amounts sufficient to provide the desired dosage in the range as described above. Thus, for oral administration, the compounds can be combined with a suitable solid or liquid carrier or diluent to form capsules, tablets, powders, syrups, solutions and suspensions. The pharmaceutical compositions, may, if desired, contain additional components such as flavourants, sweeteners and excipients. For parenteral administration, the compounds can be combined with sterile aqueous or organic media to form injectable solutions or suspensions. For example, solutions in sesame or peanut oil and aqueous propylene glycol can be used, as well as aqueous solutions of water-soluble pharmaceutically-acceptable acid addition salts or alkali or alkaline earth metal salts of the compounds. The injectable solutions prepared in this manner can then be, administered intravenously, intraperitoneally, subcutaneously, or intramuscularly, with intramuscular administration being preferred in humans.

[0056] The pharmaceutical composition of the present invention are particularly effective in lowering blood glucose, serum insulin and triglyceride levels in animal models of types II diabetes. The pharmaceutical compositions of the present invention are also effective in the treatment of obesity, inflammation, autoimmune diseases. Furthermore, pharmaceutical composition of the present invention are useful for the treatment of disorders associated with insulin resistance, such as polycystic ovary syndrome, as well as hyperlipidemia, coronary artery disease and peripheral vascular disease, and for the treatment of inflammation and immunological diseases, particularly those mediated by cytokines such as TNF- α , IL-1, IL-6 and cyclooxygenase such as COX-2.

Protocols for biological testing

[0057] Compounds of the present invention have been tested for lowering inflammatory cytokines level, chemically-induced inflammation, obesity and blood glucose, in different models for their biological activity. The attached figures 1-9. shows the activity profile of the representative compound.

FIGURE 1. Compounds 1 and 2 in Example 1 inhibit major pro-inflammatory cytokines in human monocyte cells

Human THP-1 monocyte cells were cultured and incubated with two compounds of example 1 at different concentrations. Cells were then challenged with lipopolysaccharides (LPS) at a concentration of (1 microgram/ml) for 24 hours. Cell supernatants were then analyzed for the presence of TNF α , IL1 β and IL-6 cytokines by antibody directed

enzyme-linked immunoassay. As shown in Figure 1, the example compounds can inhibit the production of three major pro-inflammatory cytokines in a dose dependent manner. No significant change in cell viability was observed with incubation of cells in the presence of highest concentration of the compound. These strongly indicate that compound of example 1 is highly effective in reducing the production of pro-inflammatory cytokines.

FIGURE 2. Compound 2 in Example 1 can lower Carrageenan induced inflammation in rats.

Spegue-Dowley rats of average weight 250g (6-7 weeks of age) were randomized in three groups, and given 50 mg/kg oral dose of compound of example 1. Thirty minutes later carrageenan was administered in the sub-planter region of right hind paws. Control group received equal volume of water without any compound. Paw volume was measured after 2 and three hours. Dexamethasone at a concentration of 5 mg/kg was used as a positive control in this experiment. As shown in Figure 2, the compound of example 1 can substantially lower the inflammation induced by carrageenan. At time 3 hours the effect of compound of example -1 was as effective as dexamethasone (a known anti-inflammatory drug that acts via different mechanism pathways).

FIGURE 3. Compounds 1 and 2 in Example 1 prevent EAE in mice (Multiple Sclerosis Model)

Multiple sclerosis (MS) is an autoimmune disease and is regulated by cytokine levels. In order to test the effect of example 1 in MS model, experimental allergic encephalomyelitis (EAE) was induced in SJL/J mice. EAE is an autoimmune inflammatory disease of the central nervous system (CNS). The disease shows many similarities with the human MS, and hence is used as a model to test the potential efficacy of new drugs that may have applicability in MS. EAE was induced by injecting spinal chord homogenate where animals were treated with example compounds. The severity of EAE was established by clinical scores of paralysis. As shown in Figure 3, the new compound treated group showed complete prevention of EAE. These results indicate utility of the example compounds for the treatment of MS and other neurological disorders.

FIGURE 4. Schematic representation of cytokine modulation and immune disorders. Macrophage produces various cytokines upon stimulation by mitogens and other unknown factors. Few of these key cytokines are known to be involved in various immunological disorders including a number of autoimmune diseases.

FIGURE 5. Direct and indirect Linkage of $TNF\alpha$ in Metabolic diseases.

It has been well established that $TNF\alpha$ plays a major role in inflammatory diseases and autoimmune disorders with treatments available for rheumatoid arthritis using antibody against $TNF\alpha$. In addition, a number of studies in recent years have predicted the possible role of $TNF\alpha$ in adipose biology and metabolic disorders such as diabetes, obesity, hyperlipidemic and vascular complications. The schematic illustration reflects how the regulation of $TNF\alpha$ can have impact on a number of metabolic diseases, that can provide different pathways for treating these diseases.

FIGURE 6. Compound 2 in Example 1 substantially improves hyperglycemia in diabetic mice.

The hypoglycemic effect of the compound has been examined in two spontaneous animal models of diabetes (ob/ob and db/db mice). The ob/ob mice lack leptin gene and is also considered a typical model for obesity. The db/db mice have defective leptin receptor and show hyperglycemia with significant weight gain. The compound at a dose of 5, 10 and 50 mg/kg body weight was given orally in these animals for a period of 15-21 days. Treatment of both ob/ob and db/db diabetic animals resulted in significant improvement of hyperglycemic conditions. Results are essentially the same for compound 1.

FIGURE 7. The Compounds 1 and 2 in Example 1 reduce body weight gain in animal model of obesity.

The leptin knock-out mice (ob/ob) are considered a suitable model for obesity besides diabetes. In order to test the efficacy of these compounds towards obesity, ob/ob mice were treated with compound for 21 days. As shown in Figure 7, single dose daily treatment of ob/ob mice with compound can result in 35% improvement in body weight gain, indicating the utility of these compounds for the treatment of obesity. This finding is opposite from that using other thiazolidines, which typically increase weight.

FIGURE 8. The Compound 2 in Example 1 can improve insulin resistance and lipid homeostasis.

The leptin knock-out ob/ob mice is also considered a good model for insulin resistance. Treatment of these animals with the compound 2 lowered serum insulin concentration by >70%. Similarly, a 48% decrease in triglyceride level and >50% decrease in serum cholesterol concentrations were observed in 15-day treatment study. These results indicate that the compounds have strong anti-lipidemic properties and can improve the sensitivity of insulin. In a separate study, surprisingly it was observed that these compounds are non-adipogenic in contrast to other known thiazolidinediones and has very weak or no affinity towards peroxisome proliferator activator receptor-gamma (PPAR- γ). All of these biological findings suggest the compounds have novel properties and work by a very different


mechanism of action from PPAR- γ binding.

FIGURE. 9. Known PPAR- γ agonist rosiglitazone is an adipogenic agent, but Compound 2 is not.

Human subcutaneous preadipocytes were cultured in 96 well plate in presence of vehicle or different doses (0.01, 0.1, 1.0, and 10 microMolar) of either rosiglitazone (BRL) or compound 2 (BLX) for 13 days. Every 72 hours media were changed with fresh compound. As TNF inhibits adipogenesis process, it was kept as negative control of the experiment where coincubation with rosiglitazone showed a significant reduction in adipogenesis compared to rosiglitazone alone. On day 13 cells were fixed and lipid (triglycerides) accumulation was measured by staining with Oil Red O and pictures were under the microscope. To have more quantitative data, Oil Red O was extracted by adding isopropanol and measured spectrophotometrically at 540 nM (as shown in the bar graph). It can be seen that regardless of dosage, compound 2 did not cause accumulation of lipids. Rosiglitazone showed a dose dependent increase in lipid production, which could be inhibited by addition of TNF α .

Claims

1. A compound of formula (I)



its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts, its pharmaceutically acceptable solvates, wherein ---- represents an optional double bond; Y represents oxygen, sulfur or NR, wherein R represents hydrogen or alkyl; Z represents oxygen or sulfur; R₁, R₂, R₃ and R₄ may be same or different and independently represent hydrogen, halogen, hydroxy, nitro, cyano, formyl, amino, alkyl, or alkoxy; A represents a bond or substituted or unsubstituted aryl, heterocyclyl or heteroaryl ring; X represents an alpha amino carboxylic acid or alpha amino carboxylic acid derivative in which the amino group is carboxylated or the carboxylic acid group is esterified or is an amide, wherein X is bonded to A or Y through its alpha side chain.

2. A compound of formula (I) according to claim 1, wherein the X-A-Y-represents an amino acid selected from the group consisting of substituted or unsubstituted arginine, asparagine, cysteine, glutamine, histidine, lysine, methionine, ornithine, proline, serine, threonine, tryptophan, tyrosine and their derivatives in which the amino group is carboxylated or the carboxylic acid group is esterified or is an amide.
3. A compound according to claim 1 wherein A represents a substituted or unsubstituted aryl, heterocyclyl or heteroaryl ring.
4. A compound according to claim 1 wherein X-A- represents an amino acid selected from the group consisting of alanine, glycine, isoleucine and leucine and their derivatives in which the amino group is carboxylated or the carboxylic acid group is esterified or is an amide.
5. A compound according to claim 1 wherein A represents a bond.
6. A compound according to any of claims 1 through 5 wherein Z is sulfur and Y is oxygen.
7. A compound according to any of claims 1 through 5 wherein R₁ through R₄ are hydrogen.
8. A compound according to any of claims 1 through 5 wherein the --- double bond is present.
9. A compound according to any of claims 1 through 5 wherein the --- double bond is absent.
10. A compound according to claim 2 wherein X-A-Y- comprises tyrosine.

11. A compound according to claim 2 wherein X-A-Y comprises a tyrosine derivative in which the amino group is carboxylated or the carboxylic acid group is esterified or is an amide.

12. A compound according to claim 11 wherein said derivative comprises an alkyl ester of tyrosine.

13. A compound according to claim 12 wherein said ester is the methyl ester.

14. A compound according to claim 10 or 11 wherein R₁, R₂, R₃ and R₄ are hydrogen and Z is sulfur.

15. A compound according to claim 14 wherein the --- double bond is present.

16. A compound according to claim 14 wherein the --- double bond is absent.

17. A compound according to claim 1, which is selected from the group consisting of:


5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)benzilidene]thiazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)benzilidene]thiazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)benzyl]thiazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)benzyl]thiazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)benzilidene]oxazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)benzilidene]oxazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)benzyl]oxazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)benzyl]oxazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2,6-difluorobenzilidene]oxazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-2,6-difluorobenzilidene] oxazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2,6-difluorobenzyl]oxazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-2,6-difluorobenzyl] oxazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2,6-difluorobenzilidene]thiazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-2,6-difluorobenzilidene] thiazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2,6-difluorobenzyl]thiazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-2,6-difluorobenzyl] thiazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2,3-difluorobenzilidene]thiazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-2,3-difluorobenzilidene] thiazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2,3-difluorobenzyl]thiazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-2,3-difluorobenzyl] thiazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2,3-difluorobenzilidene]oxazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-2,3-difluorobenzilidene] oxazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2,3-difluorobenzyl]oxazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2,3-difluorobenzyl] oxazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-methylbenzilidene]oxazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-methylbenzilidene] oxazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-methylbenzyl]oxazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-methylbenzyl]oxazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-methylbenzilidene]thiazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-methylbenzilidene] thiazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-methylbenzyl]thiazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-methylbenzyl]thiazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-nitrobenzilidene]thiazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-nitrobenzilidene] thiazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-nitrobenzyl]thiazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-nitrobenzyl]thiazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-nitrobenzilidene]oxazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-nitrobenzilidene] oxazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-nitrobenzyl]oxazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-nitrobenzyl]oxazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-aminobenzilidene]thiazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-aminobenzilidene] thiazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-aminobenzyl]thiazolidin-2,4-dione or its salts;

[illegible]

[illegible]

5-[4-(4-(2-Amino-2-carboxyethyl)-3-trifluoromethylphenoxy)benzyl]oxazolidin-2,4-dione or its salts;
 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-3-trifluoromethylphenoxy)benzyl] oxazolidin-2,4-dione or its salts;
 5-[4-(4-(2-t-butoxycarbonylamino-2-methoxycarbonylethyl)phenoxy) benzilidene] thiazolidin-2,4-dione or its salts;
 5-[4-(4-(2-t-butoxycarbonylamino-2-methoxycarbonylethyl)phenoxy) benzyl]thiazolidin-2,4-dione or its salts;
 5-[4-(4-(2-t-butoxycarbonylamino-2-methoxycarbonylethyl)phenoxy) benzilidene] oxazolidin-2,4-dione or its salts;
 5-[4-(4-(2-t-butoxycarbonylamino-2-methoxycarbonylethyl)phenoxy) benzyl]oxazolidin-2,4-dione or its salts.
 5-[4-(4-(2-t-butoxycarbonylamino-2-carboxyethyl)phenoxy) benzilidene]thiazolidin-2,4-dione or its salts;
 5-[4-(4-(2-t-butoxycarbonylamino-2-carboxyethyl)phenoxy)benzyl]thiazolidin-2,4-dione or its salts;
 5-[4-(4-(2-t-butoxycarbonylamino-2-carboxyethyl)phenoxy) benzilidene]oxazolidin-2,4-dione or its salts and
 5-[4-(4-(2-t-butoxycarbonylamino-2-carboxyethyl)phenoxy)benzyl]oxazolidin-2,4-dione or its salts.

18. A process for the preparation of an amino acid phenyl ether of formula (I)




its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts, its pharmaceutically acceptable solvates, wherein ---- represents a bond; Y represents oxygen, sulfur or NR, wherein R represents hydrogen or alkyl; Z represents oxygen or sulfur; R₁, R₂, R₃ and R₄ may be same or different and independently represent hydrogen, halogen, hydroxy, nitro, cyano, formyl, amino, alkyl, or alkoxy; A represents a bond or substituted or unsubstituted aryl, heterocyclyl or heteroaryl ring; X represents an alpha amino carboxylic acid or a derivative thereof in which the amino group is carboxylated or the carboxylic acid group is esterified or is an amide, wherein X is bounded to A or Y through its alpha side chain, which comprises


i). reacting the compound of formula (IIIa)



which represents a protected amino acid and all other symbols are as defined above with the compound of formula (IIIb)




wherein L represents a nucleophilic aromatic substitution leaving group, R₁, R₂ and R₃ are as defined above to produce a compound of formula (IIIc)




ii). reacting the compound of the formula (IIIc) with 2,4-thiazolidinedione or 2,4-oxazolidinedione to yield a

compound of formula (IIIId) and




iii). deprotecting the amino acid group of formula (IIIId) to yield compound of formula (I).

19. A process for the preparation of amino acid phenyl ethers of formula (I)




their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, wherein ---- represents no bond; Y represents oxygen, sulfur or NR, wherein R represents hydrogen or alkyl; Z represents sulfur; R₁, R₂, R₃ and R₄ may be same or different and independently represent hydrogen, halogen, hydroxy, nitro, cyano, formyl, amino, alkyl, or alkoxy; A represents a bond or substituted or unsubstituted aryl, heterocyclyl or heteroaryl ring; X represents an alpha amino carboxylic acid or a derivative thereof in which the amino group is carboxylated or the carboxylic acid group is esterified or is an amide, wherein X is bonded to A or Y through its alpha side chain, by reacting the compound of formula (IIIe)




wherein J is halogen atom and R is a lower alkyl group with thiourea followed by treatment with an acid.


20. A process for the preparation of an amino acid phenyl ether of formula (I)




its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts, its pharmaceutically acceptable solvates, wherein ---- represents a bond; Y represents oxygen, sulfur or NR, wherein R represents hydrogen, or alkyl; Z represents oxygen or sulfur; R₁, R₂, R₃ and R₄ may be same or different and independently represent hydrogen, halogen, hydroxy, nitro, cyano, formyl, amino, alkyl, or alkoxy; A represents a bond or substituted or unsubstituted aryl, heterocyclyl or heteroaryl ring; X represents an alpha amino carboxylic acid or a derivative thereof in which the amino group is carboxylated or the carboxylic acid group is esterified or is an amide, wherein X is bonded to A or Y through its alpha side chain, by reacting a compound of formula (IIIIf)




wherein L is a nucleophilic leaving group with a compound of the formula (IIIg).




21. A process for the preparation of an amino acid phenyl ether of formula (I)




its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts, its pharmaceutically acceptable solvates, wherein ---- represents a bond; Y represents oxygen, sulfur or NR, wherein R represents hydrogen or alkyl; Z represents oxygen or sulfur; R₁, R₂, R₃ and R₄ may be same or different and independently represent hydrogen, halogen, hydroxy, nitro, cyano, formyl, amino, alkyl, or alkoxy; A represents a bond or substituted or unsubstituted aryl, heterocyclyl or heteroaryl ring; X represents an alpha amino carboxylic acid or a derivative thereof in which the amino group is carboxylated or the carboxylic acid group is esterified or is an amide, wherein X is bonded to A or Y through its alpha side chain, by reacting a compound of formula (IIIg)



where A and X are as defined above with a compound of the formula (IIIg)




22. A process for the preparation of compound of formula (I)




wherein "----" represents no bond by reducing compounds of formula (I) wherein "-" represents a bond and all other symbols are as defined in claim 1.

23. A pharmaceutical composition, which comprises a pharmaceutically effective amount of an amino acid phenyl ether of formula (I)




as defined in claim 1 and a pharmaceutically acceptable carrier, diluent, excipient or solvate.

24. Compound of formula (I) according to claim 1 for use in reducing glucose in plasma.
25. Compound of formula (I) according to claim 1 for use in reducing free fatty acids in plasma.
26. Compound of formula (I) according to claim 1 for use in reducing cholesterol in plasma.
27. Compound of formula (I) according to claim 1 for use in reducing triglyceride levels in plasma.
28. Compound of formula (I) according to claim 1 for use in treating obesity.
29. Compound of formula (I) according to claim 1 for use in treating autoimmune diseases .
30. Compound of formula (I) according to claim 1 for use in treating inflammation.
31. Compound of formula (I) according to claim 1 for use in treating immunological disease.
32. Compound for use according to claim 29 wherein the autoimmune disease is multiple sclerosis.
33. Compound for use according to claim 29 wherein the autoimmune disease is rheumatoid arthritis.
34. Compound for use according to claim 30 wherein the inflammation is mediated by cyclooxygenase.
35. Compound for use according to claim 31 wherein the immunological diseases is mediated by cytokines.
36. Compound of formula (I) according to claim 1 for use in treating a disorder associated with insulin resistance.
37. An intermediate of formula (IIIc)



its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, wherein Y represents oxygen, sulfur or NR, wherein R represents hydrogen or alkyl; R₁, R₂, R₃ and R₄ may be same or different and independently represent hydrogen, halogen, hydroxy, nitro, cyano, formyl, amino, alkyl, or alkoxy; A represents substituted or unsubstituted aryl; X represents an alpha amino carboxylic acid or a derivative thereof in which the amino group is carboxylated or the carboxylic acid group is esterified or is an amide, wherein X is bonded to A or Y through its alpha side chain.

38. An intermediate of formula (IIIc)




its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts, its pharmaceutically acceptable solvates, wherein Y represents oxygen, sulfur or NR, wherein R represents hydrogen or alkyl; R_1 , R_2 , R_3 and R_4 may be same or different and independently represent hydrogen, halogen, hydroxy, nitro, cyano, formyl, amino, alkyl, or alkoxy; A represents substituted or unsubstituted aryl; X represents an alpha amino carboxylic acid or a derivative thereof in which the amino group is carboxylated or the carboxylic acid group is esterified or is an amide, wherein X is bonded to A or Y through its alpha side chain; J represents halogen atom and R_5 represents lower alkyl group.

39. The compound as claimed in claim 1, wherein said pharmaceutically acceptable salt is selected from hydrochloride, hydrobromide, sodium, potassium or magnesium salt.

Patentansprüche

1. Verbindung der Formel (I)



deren tautomere Formen, deren Stereoisomere, deren Polymorphe, deren pharmazeutisch verträgliche Salze, deren pharmazeutisch verträgliche Solvate, wobei ---- eine eventuelle Doppelbindung bedeutet, Y Sauerstoff, Schwefel oder NR bedeutet, wobei R Wasserstoff oder Alkyl bedeutet; Z Sauerstoff oder Schwefel bedeutet; R_1 , R_2 , R_3 und R_4 gleich oder verschieden sein können und unabhängig Wasserstoff, Halogen, Hydroxy, Nitro, Cyano, Formyl, Amino, Alkyl oder Alkoxy bedeuten; A bedeutet eine Bindung oder einen substituierten oder unsubstituierten Aryl-, einen substituierten oder unsubstituierten Heterocyclyl- oder einen substituierten oder unsubstituierten Heteroarylring; X bedeutet eine alpha-Aminocarbonsäure oder ein alpha-Aminocarbonsäurederivat, wobei die Aminogruppe carboxyliert ist oder die Carboxylgruppe verestert ist oder ein Amid ist, wobei X an A oder Y durch seine alpha-Seitenkette gebunden ist.

2. Verbindung der Formel (I) gemäß Anspruch 1, wobei das X-A-Y- eine Aminosäure bedeutet, ausgewählt aus der Gruppe, bestehend aus substituiertem oder unsubstituiertem Arginin, Asparagin, Cystein, Glutamin, Histidin, Lysin, Methionin, Ornithin, Prolin, Serin, Threonin, Tryptophan, Tyrosin und deren Derivaten, wobei die Aminogruppe carboxyliert ist oder die Carboxylgruppe verestert ist oder ein Amid ist.
3. Verbindung gemäß Anspruch 1, wobei A einen substituierten oder unsubstituierten Aryl-, einen substituierten oder unsubstituierten Heterocyclyl- oder einen substituierten oder unsubstituierten Heteroarylring bedeutet.
4. Verbindung gemäß Anspruch 1, wobei X-A- eine Aminosäure bedeutet, ausgewählt aus der Gruppe, bestehend aus Alanin, Glycin, Isoleucin und Leucin und deren Derivaten, wobei die Aminogruppe carboxyliert ist oder die Carboxylgruppe verestert ist oder ein Amid ist.
5. Verbindung gemäß Anspruch 1, wobei A eine Bindung bedeutet.
6. Verbindung gemäß einem beliebigen der Ansprüche 1 bis 5, wobei Z Schwefel ist und Y Sauerstoff ist.
7. Verbindung gemäß einem beliebigen der Ansprüche 1 bis 5, wobei R_1 bis R_4 Wasserstoff sind.


8. Verbindung gemäß einem beliebigen der Ansprüche 1 bis 5, wobei die --- Doppelbindung vorhanden ist.
9. Verbindung gemäß einem beliebigen der Ansprüche 1 bis 5, wobei die --- Doppelbindung nicht vorhanden ist.
- 5 10. Verbindung gemäß Anspruch 2, wobei X-A-Y- Tyrosin umfasst.
11. Verbindung gemäß Anspruch 2, wobei X-A-Y- ein Tyrosinderivat umfasst, wobei die Aminogruppe carboxyliert ist oder die Carboxylgruppe verestert ist oder ein Amid ist.
- 10 12. Verbindung gemäß Anspruch 11, wobei das Derivat einen Alkylester von Tyrosin umfasst.
13. Verbindung gemäß Anspruch 12, wobei der Ester der Methylester ist.
14. Verbindung gemäß Anspruch 10 oder 11, wobei R₁, R₂, R₃ und R₄ Wasserstoff sind und Z Schwefel ist.
- 15 15. Verbindung gemäß Anspruch 14, wobei die --- Doppelbindung vorhanden ist.
16. Verbindung gemäß Anspruch 14, wobei die --- Doppelbindung nicht vorhanden ist.
- 20 17. Verbindung gemäß Anspruch 1, welche ausgewählt ist aus der Gruppe, bestehend aus:
 - 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)benziliden]thiazolidin-2,4-dion oder dessen Salze;
 - 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)benziliden]thiazolidin-2,4-dion oder dessen Salze;
 - 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)benzyl]thiazolidin-2,4-dion oder dessen Salze;
 - 25 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)benzyl]thiazolidin-2,4-dion oder dessen Salze;
 - 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)benziliden]oxazolidin-2,4-dion oder dessen Salze;
 - 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)benziliden]oxazolidin-2,4-dion oder dessen Salze;
 - 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)benzyl]oxazolidin-2,4-dion oder dessen Salze;
 - 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)benzyl]oxazolidin-2,4-dion oder dessen Salze;
 - 30 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2,6-difluorbenziliden]oxazolidin-2,4-dion oder dessen Salze;
 - 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-2,6-difluorbenziliden]oxazolidin-2,4-dion oder dessen Salze;
 - 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2,6-difluorbenzyl]oxazolidin-2,4-dion oder dessen Salze;
 - 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-2,6-difluorbenzyl]oxazolidin-2,4-dion oder dessen Salze;
 - 35 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2,6-difluorbenziliden]thiazolidin-2,4-dion oder dessen Salze;
 - 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-2,6-difluorbenziliden]thiazolidin-2,4-dion oder dessen Salze;
 - 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2,6-difluorbenzyl]thiazolidin-2,4-dion oder dessen Salze;
 - 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-2,6-difluorbenzyl]thiazolidin-2,4-dion oder dessen Salze;
 - 40 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2,3-difluorbenziliden]thiazolidin-2,4-dion oder dessen Salze;
 - 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-2,3-difluorbenziliden]thiazolidin-2,4-dion oder dessen Salze;
 - 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2,3-difluorbenzyl]thiazolidin-2,4-dion oder dessen Salze;
 - 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-2,3-difluorbenzyl]thiazolidin-2,4-dion oder dessen Salze;
 - 45 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2,3-difluorbenziliden]oxazolidin-2,4-dion oder dessen Salze;
 - 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-2,3-difluorbenziliden]oxazolidin-2,4-dion oder dessen Salze;
 - 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-2,3-difluorbenzyl]oxazolidin-2,4-dion oder dessen Salze;
 - 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-2,3-difluorbenzyl]oxazolidin-2,4-dion oder dessen Salze;
 - 50 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-methylbenziliden]oxazolidin-2,4-dion oder dessen Salze;
 - 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-methylbenziliden]oxazolidin-2,4-dion oder dessen Salze;
 - 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-methylbenzyl]oxazolidin-2,4-dion oder dessen Salze;
 - 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-methylbenzyl]oxazolidin-2,4-dion oder dessen Salze;
 - 55 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-methylbenziliden]thiazolidin-2,4-dion oder dessen Salze;
 - 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-methylbenziliden]thiazolidin-2,4-dion oder dessen Salze;
 - 5-[4-(4-(2-Amino-2-carboxyethyl)phenoxy)-3-methylbenzyl]thiazolidin-2,4-dion oder dessen Salze;
 - 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)phenoxy)-3-methylbenzyl]thiazolidin-2,4-dion oder dessen Salze;

[illegible]

[illegible]

5-[4-(4-(2-Amino-2-carboxyethyl)-3-fluorophenoxy)benzyl]thiazolidin-2,4-dion oder dessen Salze;
 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-3-fluorophenoxy)benzyl]thiazolidin-2,4-dion oder dessen Salze;
 5-[4-(4-(2-Amino-2-carboxyethyl)-3-fluorophenoxy)benziliden]oxazolidin-2,4-dion oder dessen Salze;
 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-3-fluorophenoxy)benziliden]oxazolidin-2,4-dion oder dessen Salze;
 5-[4-(4-(2-Amino-2-carboxyethyl)-3-fluorophenoxy)benzyl]oxazolidin-2,4-dion oder dessen Salze;
 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-3-fluorophenoxy)benzyl]oxazolidin-2,4-dion oder dessen Salze;
 5-[4-(4-(2-Amino-2-carboxyethyl)-2-trifluormethylphenoxy)benziliden]thiazolidin-2,4-dion oder dessen Salze;
 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-2-trifluormethylphenoxy)benziliden]thiazolidin-2,4-dion oder des-
 sen Salze;
 5-[4-(4-(2-Amino-2-carboxyethyl)-2-trifluormethylphenoxy)benzyl]thiazolidin-2,4-dion oder dessen Salze;
 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-2-trifluormethylphenoxy)benzyl]thiazolidin-2,4-dion oder dessen
 Salze;
 5-[4-(4-(2-Amino-2-carboxyethyl)-2-trifluormethylphenoxy)benziliden]oxazolidin-2,4-dion oder dessen Salze;
 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-2-trifluormethylphenoxy)benziliden]oxazolidin-2,4-dion oder des-
 sen Salze;
 5-[4-(4-(2-Amino-2-carboxyethyl)-2-trifluormethylphenoxy)benzyl]oxazolidin-2,4-dion oder dessen Salze;
 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-2-trifluormethylphenoxy)benzyl]oxazolidin-2,4-dion oder dessen
 Salze;
 5-[4-(4-(2-Amino-2-carboxyethyl)-3-trifluormethylphenoxy)benziliden]thiazolidin-2,4-dion oder dessen Salze;
 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-3-trifluormethylphenoxy)benziliden]thiazolidin-2,4-dion oder des-
 sen Salze;
 5-[4-(4-(2-Amino-2-carboxyethyl)-3-trifluormethylphenoxy)benzyl]thiazolidin-2,4-dion oder dessen Salze;
 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-3-trifluormethylphenoxy)benzyl]thiazolidin-2,4-dion oder dessen
 Salze;
 5-[4-(4-(2-Amino-2-carboxyethyl)-3-trifluormethylphenoxy)benziliden]oxazolidin-2,4-dion oder dessen Salze;
 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-3-trifluormethylphenoxy)benziliden]oxazolidin-2,4-dion oder des-
 sen Salze;
 5-[4-(4-(2-Amino-2-carboxyethyl)-3-trifluormethylphenoxy)benzyl]oxazolidin-2,4-dion oder dessen Salze;
 5-[4-(4-(2-Amino-2-methoxycarbonylethyl)-3-trifluormethylphenoxy)benzyl]oxazolidin-2,4-dion oder dessen
 Salze;
 5-[4-(4-(2-t-Butoxycarbonylamino-2-methoxycarbonylethyl)phenoxy)benziliden]thiazolidin-2,4-dion oder des-
 sen Salze;
 5-[4-(4-(2-t-Butoxycarbonylamino-2-methoxycarbonylethyl)phenoxy)benzyl]thiazolidin-2,4-dion oder dessen
 Salze;
 5-[4-(4-(2-t-Butoxycarbonylamino-2-methoxycarbonylethyl)phenoxy)benziliden]oxazolidin-2,4-dion oder des-
 sen Salze;
 5-[4-(4-(2-t-Butoxycarbonylamino-2-methoxycarbonylethyl)phenoxy)benzyl]oxazolidin-2,4-dion oder dessen
 Salze;
 5-[4-(4-(2-t-Butoxycarbonylamino-2-carboxyethyl)phenoxy)benziliden]thiazolidin-2,4-dion oder dessen Salze;
 5-[4-(4-(2-t-Butoxycarbonylamino-2-carboxyethyl)phenoxy)benzyl]thiazolidin-2,4-dion oder dessen Salze;
 5-[4-(4-(2-t-Butoxycarbonylamino-2-carboxyethyl)phenoxy)benziliden]oxazolidin-2,4-dion oder dessen Salze
 und
 5-[4-(4-(2-t-Butoxycarbonylamino-2-carboxyethyl)phenoxy)benzyl]oxazolidin-2,4-dion oder dessen Salze.

18. Verfahren zur Herstellung eines Aminosäurephenylethers der Formel (I)




dessen tautomerer Formen, dessen Stereoisomeren, dessen Polymorphen, dessen pharmazeutisch verträglichen
 Salzen, dessen pharmazeutisch verträglichen Solvaten, wobei ---- eine Doppelbindung bedeutet; Y Sauerstoff,
 Schwefel oder NR bedeutet, wobei R Wasserstoff oder Alkyl bedeutet; Z Sauerstoff oder Schwefel bedeutet; R₁,
 R₂, R₃ und R₄ gleich oder verschieden sein können und unabhängig Wasserstoff, Halogen, Hydroxy, Nitro, Cyano,

Formyl, Amino, Alkyl oder Alkoxy bedeuten; A bedeutet eine Bindung oder einen substituierten oder unsubstituierten Aryl-; substituierten oder unsubstituierten Heterocycl- oder substituierten oder unsubstituierten Heteroarylring; X bedeutet eine alpha-Aminocarbonsäure oder ein Derivat davon, wobei die Aminogruppe carboxyliert ist oder die Carboxylgruppe verestert ist, oder ein Amid ist, wobei X an A oder Y durch eine alpha-Seitenkette gebunden ist, das umfasst:


i) Umsetzen der Verbindung der Formel (IIIa)




welche eine geschützte Aminosäure darstellt, wobei alle anderen Symbole wie oben definiert sind, mit der Verbindung der Formel (IIIb)



wobei L eine Abgangsgruppe für die nukleophile aromatische Substitution bedeutet, R_1 , R_2 und R_3 wie oben definiert sind, unter Bildung einer Verbindung der Formel (IIIc)




ii) Umsetzen der Verbindung der Formel (IIIc) mit 2,4-Thiazolidindion oder 2,4-Oxazolidindion zur Gewinnung einer Verbindung der Formel (IIId) und




iii) Entschützen der Aminosäuregruppe der Formel (IIId) zur Gewinnung der Formel (I).

19. Verfahren zur Herstellung von Aminosäurephenylethern der Formel (I)




deren tautomerer Formen, deren Stereoisomeren, deren Polymorphen, deren pharmazeutisch verträglichen Salzen, deren pharmazeutisch verträglichen Solvaten, wobei --- keine Bindung bedeutet, Y Sauerstoff, Schwefel oder NR bedeutet, wobei R Wasserstoff oder Alkyl bedeutet; Z bedeutet Schwefel, R_1 , R_2 , R_3 und R_4 können gleich oder

verschieden sein und bedeuten unabhängig Wasserstoff, Halogen, Hydroxy, Nitro, Cyano, Formyl, Amino, Alkyl oder Alkoxy; A bedeutet eine Bindung oder einen substituierten oder unsubstituierten Aryl-, einen substituierten oder unsubstituierten Heterocyclyl- oder einen substituierten oder unsubstituierten Heteroarylring; X bedeutet eine alpha-Aminocarbonsäure oder ein Derivat davon, wobei die Aminogruppe carboxyliert ist oder die Carbonsäuregruppe verestert ist oder ein Amid ist, wobei X an A oder Y durch seine alpha-Seitenkette gebunden ist, durch Umsetzen der Verbindung der Formel (IIIe)



wobei J ein Halogenatom ist, und R ist eine Niedrigalkylgruppe, mit Thioharnstoff, gefolgt von Behandlung mit einer Säure.


20. Verfahren zur Herstellung eines Aminosäurephenylethers der Formel (I)




dessen tautomerer Formen, dessen Stereoisomeren, dessen Polymorphen, dessen pharmazeutisch verträglichen Salzen, dessen pharmazeutisch verträglichen Solvaten, wobei ---- eine Bindung bedeutet, Y Sauerstoff, Schwefel oder NR bedeutet, wobei R Wasserstoff oder Alkyl bedeutet; Z bedeutet Sauerstoff oder Schwefel, R_1 , R_2 , R_3 und R_4 können gleich oder verschieden sein und bedeuten unabhängig Wasserstoff, Halogen, Hydroxy, Nitro, Cyano, Formyl, Amino, Alkyl oder Alkoxy; A bedeutet eine Bindung oder einen substituierten oder unsubstituierten Aryl-, einen substituierten oder unsubstituierten Heterocyclyl- oder einen substituierten oder unsubstituierten Heteroarylring; X bedeutet eine alpha-Aminocarbonsäure oder ein Derivat davon, wobei die Aminogruppe carboxyliert ist oder die Carbonsäuregruppe verestert ist oder ein Amid ist, wobei X an A oder Y durch seine alpha-Seitenkette gebunden ist, durch Umsetzen der Verbindung der Formel (IIIf)




wobei L eine nukleophile Abgangsgruppe ist, mit einer Verbindung der Formel (IIIg)




21. Verfahren zur Herstellung eines Aminosäurephenylethers der Formel (I)




dessen tautomerer Formen, dessen Stereoisomeren, dessen Polymorphen, dessen pharmazeutisch verträglichen Salzen, dessen pharmazeutisch verträglichen Solvaten, wobei ---- eine Bindung bedeutet, Y Sauerstoff, Schwefel oder NR bedeutet, wobei R Wasserstoff oder Alkyl bedeutet; Z bedeutet Sauerstoff oder Schwefel, R₁, R₂, R₃ und R₄ können gleich oder verschieden sein und bedeuten unabhängig Wasserstoff, Halogen, Hydroxy, Nitro, Cyano, Formyl, Amino, Alkyl oder Alkoxy; A bedeutet eine Bindung oder einen substituierten oder unsubstituierten Aryl-, einen substituierten oder unsubstituierten Heterocycl- oder einen substituierten oder unsubstituierten Heteroarylring; X bedeutet eine alpha-Aminocarbonsäure oder ein Derivat davon, wobei die Aminogruppe carboxyliert ist oder die Carbonsäuregruppe verestert ist oder ein Amid ist, wobei X an A oder Y durch seine alpha-Seitenkette gebunden ist, durch Umsetzen einer Verbindung der Formel (IIIh)



wobei A und X wie oben definiert sind, mit einer Verbindung der Formel (IIIg)




22. Verfahren zur Herstellung einer Verbindung der Formel (I)




wobei "----" keine Bindung bedeutet, durch Reduktion von Verbindungen der Formel (I), wobei "----" eine Bindung bedeutet, und alle übrigen Symbole wie in Anspruch 1 definiert sind.

23. Pharmazeutische Zusammensetzung, welche eine pharmazeutisch wirksame Menge eines Aminosäurephenylethers der Formel (I)




wie in Anspruch 1 definiert und einen pharmazeutisch verträglichen Träger, ein pharmazeutisch verträgliches Diluens, ein pharmazeutisch verträgliches Exzipiens oder ein pharmazeutisch verträgliches Solvat umfasst.

24. Verbindung der Formel (I) gemäß Anspruch 1 zur Verwendung zur Verringerung von Glucose in Plasma.
25. Verbindung der Formel (I) gemäß Anspruch 1 zur Verwendung zur Verringerung von freien Fettsäuren in Plasma.
26. Verbindung der Formel (I) gemäß Anspruch 1 zur Verwendung zur Verringerung von Cholesterol in Plasma.
27. Verbindung der Formel (I) gemäß Anspruch 1 zur Verwendung zur Verringerung von Triglyceridspiegeln in Plasma.
28. Verbindung der Formel (I) gemäß Anspruch 1 zur Verwendung zur Behandlung von Adipositas.
29. Verbindung der Formel (I) gemäß Anspruch 1 zur Verwendung zur Behandlung von Autoimmunkrankheiten.
30. Verbindung der Formel (I) gemäß Anspruch 1 zur Verwendung zur Behandlung von Entzündung.
31. Verbindung der Formel (I) gemäß Anspruch 1 zur Verwendung zur Behandlung einer immunologischen Krankheit.
32. Verbindung zur Verwendung gemäß Anspruch 29, wobei die Autoimmunkrankheit multiple Sklerose ist.
33. Verbindung zur Verwendung gemäß Anspruch 29, wobei die Autoimmunkrankheit rheumatoide Arthritis ist.
34. Verbindung zur Verwendung gemäß Anspruch 30, wobei die Entzündung durch Cyclooxygenase vermittelt ist.
35. Verbindung zur Verwendung gemäß Anspruch 31, wobei die immunologische Krankheit durch Cytokine vermittelt ist.
36. Verbindung gemäß Formel (I) gemäß Anspruch 1 zur Verwendung in der Behandlung einer mit Insulinresistenz assoziierten Störung.
37. Intermediat der Formel (IIIc)



dessen tautomere Formen, dessen Stereoisomere, dessen Polymorphe, dessen pharmazeutisch verträgliche Salze, dessen pharmazeutisch verträgliche Solvate, wobei Y Sauerstoff, Schwefel oder NR bedeutet, wobei R Wasserstoff oder Alkyl bedeutet; R₁, R₂, R₃ und R₄ können gleich oder verschieden sein und bedeuten unabhängig Wasserstoff, Halogen, Hydroxy, Nitro, Cyano, Formyl, Amino, Alkyl oder Alkoxy; A bedeutet eine Bindung oder einen substituierten oder unsubstituierten Arylring; X bedeutet eine alpha-Aminocarbonsäure oder ein Derivat davon, wobei die Aminogruppe carboxyliert ist oder die Carbonsäuregruppe verestert ist oder ein Amid ist, wobei X an A oder Y durch seine alpha-Seitenkette gebunden ist.

38. Intermediat der Formel (IIIe)




dessen tautomere Formen, dessen Stereoisomere, dessen Polymorphe, dessen pharmazeutisch verträgliche Salze, dessen pharmazeutisch verträgliche Solvate, wobei Y Sauerstoff, Schwefel oder NR bedeutet, wobei R Wasserstoff oder Alkyl bedeutet; R₁, R₂, R₃ und R₄ können gleich oder verschieden sein und bedeuten unabhängig Wasserstoff, Halogen, Hydroxy, Nitro, Cyano, Formyl, Amino, Alkyl oder Alkoxy; A bedeutet Aryl; X bedeutet eine alpha-Aminocarbonsäure oder ein Derivat davon, wobei die Aminogruppe carboxyliert ist oder die Carbonsäuregruppe verestert

ist oder ein Amid ist, wobei X an A oder Y durch seine alpha-Seitenkette gebunden ist, J bedeutet ein Halogenatom und R₅ bedeutet eine Niedrigalkylgruppe.

39. Verbindung wie in Anspruch 1 beansprucht, wobei das pharmazeutisch verträgliche Salz ausgewählt ist aus Hydrochlorid, Hydrobromid, Natrium-, Kalium- oder Magnesiumsalz.

Revendications

1. Composé de formule (I)



ses formes tautomères, ses stéréoisomères, ses polymorphes, ses sels pharmaceutiquement acceptables, ses solvates pharmaceutiquement acceptables, formule dans laquelle ---- représente une double liaison facultative; Y représente l'oxygène, le soufre ou NR, où R représente l'hydrogène ou un alkyle; Z représente l'oxygène ou le soufre; R₁, R₂, R₃ et R₄ peuvent être identiques ou différents et représentent indépendamment l'hydrogène, un halogène, hydroxy, nitro, cyano, formyle, amino, alkyle ou alcoxy; A représente une liaison ou un cycle aryle, hétérocyclyle ou hétéroaryle substitué ou non substitué; X représente un acide alpha-aminocarboxylique ou un dérivé d'acide alpha-aminocarboxylique dans lequel le groupe amino est carboxylé ou le groupe acide carboxylique est estérifié ou est un amide, X étant lié à A ou Y par l'intermédiaire de sa chaîne latérale alpha.

2. Composé de formule (I) selon la revendication 1, dans lequel X-A-Y- représente un acide aminé choisi dans le groupe constitué par les acides aminés substitués ou non substitués arginine, asparagine, cystéine, glutamine, histidine, lysine, méthionine, ornithine, proline, sérine, thréonine, tryptophane, tyrosine et leurs dérivés dans lesquels le groupe amino est carboxylé ou le groupe acide carboxylique est estérifié ou est un amide.
3. Composé selon la revendication 1, dans lequel A représente un cycle aryle, hétérocyclyle ou hétéroaryle substitué ou non substitué.
4. Composé selon la revendication 1, dans lequel X-A- représente un acide aminé choisi dans l'ensemble constitué par l'alanine, la glycine, l'isoleucine et la leucine et leurs dérivés dans lesquels le groupe amino est carboxylé ou le groupe acide carboxylique est estérifié ou est un amide.
5. Composé selon la revendication 1, dans lequel A représente une liaison.
6. Composé selon l'une quelconque des revendications 1 à 5, dans lequel Z est le soufre et Y est l'oxygène.
7. Composé selon l'une quelconque des revendications 1 à 5, dans lequel R₁ à R₄ sont des hydrogènes.
8. Composé selon l'une quelconque des revendications 1 à 5, dans lequel la double liaison ---- est présente.
9. Composé selon l'une quelconque des revendications 1 à 5, dans lequel la double liaison ---- est absente.
10. Composé selon la revendication 2, dans lequel X-A-Y- comprend la tyrosine.
11. Composé selon la revendication 2, dans lequel X-A-Y- comprend un dérivé de tyrosine dans lequel le groupe amino est carboxylé ou le groupe acide carboxylique est estérifié ou est un amide.
12. Composé selon la revendication 11, dans lequel ledit dérivé comprend un ester alkylique de tyrosine.
13. Composé selon la revendication 12, dans lequel ledit ester est l'ester méthylique.

14. Composé selon la revendication 10 ou 11, dans lequel R_1 , R_2 , R_3 et R_4 sont des hydrogènes et Z est le soufre.

15. Composé selon la revendication 14, dans lequel la double liaison ---- est présente.

5 16. Composé selon la revendication 14, dans lequel la double liaison ---- est absente.

17. Composé selon la revendication 1, qui est choisi dans le groupe constitué par :

- 10 la 5-[4-(4-(2-amino-2-carboxyéthyl)phénoxy)-benzylidène]thiazolidin-2,4-dione ou ses sels ;
la 5-[4-(4-(2-amino-2-méthoxycarbonyléthyl)phénoxy)-benzylidène]thiazolidin-2,4-dione ou ses sels ;
la 5-[4-(4-(2-amino-2-carboxyéthyl)phénoxy)benzyl]thiazolidin-2,4-dione ou ses sels ;
la 5-[4-(4-(2-amino-2-méthoxycarbonyléthyl)phénoxy)-benzyl]thiazolidin-2,4-dione ou ses sels ;
la 5-[4-(4-(2-amino-2-carboxyéthyl)phénoxy)-benzylidène]oxazolidine-2,4-dione ou ses sels ;
15 la 5-[4-(4-(2-amino-2-méthoxycarbonyléthyl)phénoxy)-benzylidène]oxazolidine-2,4-dione ou ses sels ;
la 5-[4-(4-(2-amino-2-carboxyéthyl)phénoxy)benzyl]oxazolidine-2,4-dione ou ses sels ;
la 5-[4-(4-(2-amino-2-méthoxycarbonyléthyl)phénoxy)-benzyl]oxazolidine-2,4-dione ou ses sels ;
la 5-[4-(4-(2-amino-2-carboxyéthyl)phénoxy)-2,6-difluorobenzylidène]oxazolidine-2,4-dione ou ses sels ;
la 5-[4-(4-(2-amino-2-méthoxycarbonyléthyl)phénoxy)-2,6-difluorobenzylidène]oxazolidine-2,4-dione ou ses
20 sels ;
la 5-[4-(4-(2-amino-2-carboxyéthyl)phénoxy)-2,6-difluorobenzyl]oxazolidine-2,4-dione ou ses sels ;
la 5-[4-(4-(2-amino-2-méthoxycarbonyléthyl)phénoxy)-2,6-difluorobenzyl]oxazolidine-2,4-dione ou ses sels ;
la 5-[4-(4-(2-amino-2-carboxyéthyl)phénoxy)-2,6-difluorobenzylidène]thiazolidin-2,4-dione ou ses sels ;
la 5-[4-(4-(2-amino-2-méthoxycarbonyléthyl)phénoxy)-2,6-difluorobenzylidène]thiazolidin-2,4-dione ou ses
25 sels ;
la 5-[4-(4-(2-amino-2-carboxyéthyl)phénoxy)-2,6-difluorobenzyl]thiazolidin-2,4-dione ou ses sels ;
la 5-[4-(4-(2-amino-2-méthoxycarbonyléthyl)phénoxy)-2,6-difluorobenzyl]thiazolidin-2,4-dione ou ses sels ;
la 5-[4-(4-(2-amino-2-carboxyéthyl)phénoxy)-2,3-difluorobenzylidène]thiazolidin-2,4-dione ou ses sels ;
la 5-[4-(4-(2-amino-2-méthoxycarbonyléthyl)phénoxy)-2,3-difluorobenzylidène]thiazolidin-2,4-dione ou ses
30 sels ;
la 5-[4-(4-(2-amino-2-carboxyéthyl)phénoxy)-2,3-difluorobenzyl]thiazolidin-2,4-dione ou ses sels ;
la 5-[4-(4-(2-amino-2-méthoxycarbonyléthyl)phénoxy)-2,3-difluorobenzyl]thiazolidin-2,4-dione ou ses sels ;
la 5-[4-(4-(2-amino-2-carboxyéthyl)phénoxy)-2,3-difluorobenzylidène]oxazolidine-2,4-dione ou ses sels ;
la 5-[4-(4-(2-amino-2-méthoxycarbonyléthyl)phénoxy)-2,3-difluorobenzylidène]oxazolidine-2,4-dione ou ses
35 sels ;
la 5-[4-(4-(2-amino-2-carboxyéthyl)phénoxy)-2,3-difluorobenzyl]oxazolidine-2,4-dione ou ses sels ;
la 5-[4-(4-(2-amino-2-méthoxycarbonyléthyl)phénoxy)-2,3-difluorobenzyl]oxazolidine-2,4-dione ou ses sels ;
la 5-[4-(4-(2-amino-2-carboxyéthyl)phénoxy)-3-méthyl-benzylidène]oxazolidine-2,4-dione ou ses sels ;
la 5-[4-(4-(2-amino-2-méthoxycarbonyléthyl)phénoxy)-3-méthylbenzylidène]oxazolidine-2,4-dione ou ses
40 sels ;
la 5-[4-(4-(2-amino-2-carboxyéthyl)phénoxy)-3-méthyl-benzyl]oxazolidine-2,4-dione ou ses sels ;
la 5-[4-(4-(2-amino-2-méthoxycarbonyléthyl)phénoxy)-3-méthylbenzyl]oxazolidine-2,4-dione ou ses sels ;
la 5-[4-(4-(2-amino-2-carboxyéthyl)phénoxy)-3-méthyl-benzylidène]thiazolidine-2,4-dione ou ses sels ;
la 5-[4-(4-(2-amino-2-méthoxycarbonyléthyl)phénoxy)-3-méthylbenzylidène]thiazolidine-2,4-dione ou ses
45 sels ;
la 5-[4-(4-(2-amino-2-carboxyéthyl)phénoxy)-3-méthyl-benzyl]thiazolidine-2,4-dione ou ses sels ;
la 5-[4-(4-(2-amino-2-méthoxycarbonyléthyl)phénoxy)-3-méthylbenzyl]thiazolidine-2,4-dione ou ses sels ;
la 5-[4-(4-(2-amino-2-carboxyéthyl)phénoxy)-3-nitro-benzylidène]thiazolidine-2,4-dione ou ses sels ;
la 5-[4-(4-(2-amino-2-méthoxycarbonyléthyl)phénoxy)-3-nitrobenzylidène]thiazolidine-2,4-dione ou ses sels ;
la 5-[4-(4-(2-amino-2-carboxyéthyl)phénoxy)-3-nitro-benzyl]thiazolidine-2,4-dione ou ses sels ;
50 la 5-[4-(4-(2-amino-2-méthoxycarbonyléthyl)phénoxy)-3-nitrobenzyl]thiazolidine-2,4-dione ou ses sels ;
la 5-[4-(4-(2-amino-2-carboxyéthyl)phénoxy)-3-nitro-benzylidène]oxazolidine-2,4-dione ou ses sels ;
la 5-[4-(4-(2-amino-2-méthoxycarbonyléthyl)phénoxy)-3-nitrobenzylidène]oxazolidine-2,4-dione ou ses sels ;
la 5-[4-(4-(2-amino-2-carboxyéthyl)phénoxy)-3-nitro-benzyl]oxazolidine-2,4-dione ou ses sels ;
la 5-[4-(4-(2-amino-2-méthoxycarbonyléthyl)phénoxy)-3-nitrobenzyl]oxazolidine-2,4-dione ou ses sels ;
55 la 5-[4-(4-(2-amino-2-carboxyéthyl)phénoxy)-3-amino-benzylidène]thiazolidine-2,4-dione ou ses sels ;
la 5-[4-(4-(2-amino-2-méthoxycarbonyléthyl)phénoxy)-3-aminobenzylidène]thiazolidine-2,4-dione ou ses sels ;
la 5-[4-(4-(2-amino-2-carboxyéthyl)phénoxy)-3-amino-benzyl]thiazolidine-2,4-dione ou ses sels ;
la 5-[4-(4-(2-amino-2-méthoxycarbonyléthyl)phénoxy)-3-aminobenzyl]thiazolidine-2,4-dione ou ses sels ;

[illegible]

ses sels ;

la 5-[4-(4-(2-amino-2-carboxyéthyl)-2-trifluoro-méthylphénoxy)benzyl]oxazolidine-2,4-dione ou ses sels ;

la 5-[4-(4-(2-amino-2-méthoxycarbonyléthyl)-2-tri-fluorométhylphénoxy)benzyl]oxazolidine-2,4-dione ou ses sels ;

la 5-[4-(4-(2-amino-2-carboxyéthyl)-3-trifluoro-méthylphénoxy)benzylidène]thiazolidine-2,4-dione ou ses sels ;

la 5-[4-(4-(2-amino-2-méthoxycarbonyléthyl)-3-tri-fluorométhylphénoxy)benzylidène]thiazolidine-2,4-dione ou ses sels ;

la 5-[4-(4-(2-amino-2-carboxyéthyl)-3-trifluoro-méthylphénoxy)benzyl]thiazolidine-2,4-dione ou ses sels ;

la 5-[4-(4-(2-amino-2-méthoxycarbonyléthyl)-3-tri-fluorométhylphénoxy)benzyl]thiazolidine-2,4-dione ou ses sels ;

la 5-[4-(4-(2-amino-2-carboxyéthyl)-3-trifluoro-méthylphénoxy)benzylidène]oxazolidine-2,4-dione ou ses sels ;

la 5-[4-(4-(2-amino-2-méthoxycarbonyléthyl)-3-tri-fluorométhylphénoxy)benzylidène]oxazolidine-2,4-dione ou ses sels ;

la 5-[4-(4-(2-amino-2-carboxyéthyl)-3-trifluoro-méthylphénoxy)benzyl]oxazolidine-2,4-dione ou ses sels ;

la 5-[4-(4-(2-t-butoxycarbonylamino-2-méthoxy-carbonyléthyl)phénoxy)benzylidène]thiazolidine-2,4-dione ou ses sels ;

la 5-[4-(4-(2-t-butoxycarbonylamino-2-méthoxy-carbonyléthyl)phénoxy)benzyl]thiazolidine-2,4-dione ou ses sels ;

la 5-[4-(4-(2-t-butoxycarbonylamino-2-méthoxy-carbonyléthyl)phénoxy)benzylidène]oxazolidine-2,4-dione ou ses sels ;

la 5-[4-(4-(2-t-butoxycarbonylamino-2-méthoxy-carbonyléthyl)phénoxy)benzyl]oxazolidine-2,4-dione ou ses sels ;

la 5-[4-(4-(2-t-butoxycarbonylamino-2-carboxyéthyl)-phénoxy)benzylidène]thiazolidine-2,4-dione ou ses sels ;


la 5-[4-(4-(2-t-butoxycarbonylamino-2-carboxyéthyl)-phénoxy)benzyl]thiazolidine-2,4-dione ou ses sels ;

la 5-[4-(4-(2-t-butoxycarbonylamino-2-carboxyéthyl)-phénoxy)benzylidène]oxazolidine-2,4-dione ou ses sels ;

et


la 5-[4-(4-(2-t-butoxycarbonylamino-2-carboxyéthyl)-phénoxy)benzyl]oxazolidine-2,4-dione ou ses sels.

18. Procédé pour la préparation d'un éther phénylique d'acide aminé de formule (I)




de ses formes tautomères, de ses stéréoisomères, de ses polymorphes, de ses sels pharmaceutiquement acceptables, de ses solvates pharmaceutiquement acceptables, formule dans laquelle ---- représente une liaison ; Y représente l'oxygène, le soufre ou NR, où R représente l'hydrogène ou un alkyle ; Z représente l'oxygène ou le soufre ; R₁, R₂, R₃ et R₄ peuvent être identiques ou différents et représentent indépendamment l'hydrogène, un halogène, hydroxy, nitro, cyano, formyle, amino, alkyle ou alcoxy ; A représente une liaison ou un cycle aryle, hétérocyclyle ou hétéroaryle substitué ou non substitué ; X représente un acide alpha-aminocarboxylique ou un dérivé de celui-ci dans lequel le groupe amino est carboxylé ou le groupe acide carboxylique est estérifié ou est un amide, X étant lié à A ou Y par l'intermédiaire de sa chaîne latérale alpha, qui comprend


i) la réaction du composé de formule (IIIa)




qui représente un acide aminé protégé, tous les autres symboles étant tels que définis ci-dessus, avec le composé de formule (IIIb)



dans laquelle L représente un groupe partant à substitution aromatique nucléophile, R_1 , R_2 et R_3 sont tels que définis ci-dessus, pour produire un composé de formule (IIIc)




ii) la réaction du composé de formule (IIIc) avec de la 2,4-thiazolidinedione ou de la 2,4-oxazolidinedione pour engendrer un composé de formule (IIId) et




iii) la déprotection du groupe acide aminé de formule (IIId) pour engendrer un composé de formule (I).

19. Procédé pour la préparation d'éthers phénoliques d'acide aminé de formule (I)




de leurs formes tautomères, de leurs stéréoisomères, de leurs polymorphes, de leurs sels pharmaceutiquement acceptables, de leurs solvates pharmaceutiquement acceptables, formule dans laquelle ---- représente une absence de liaison ; Y représente l'oxygène, le soufre ou NR, où R représente l'hydrogène ou un alkyle ; Z représente le soufre ; R_1 , R_2 , R_3 et R_4 peuvent être identiques ou différents et représentent indépendamment l'hydrogène, un halogène, hydroxy, nitro, cyano, formyle, amino, alkyle ou alcoxy ; A représente une liaison ou un cycle aryle, hétérocyclyle ou hétéroaryle substitué ou non substitué ; X représente un acide alpha-aminocarboxylique ou un dérivé de celui-ci dans lequel le groupe amino est carboxylé ou le groupe acide carboxylique est estérifié ou est un amide, X étant lié à A ou Y par l'intermédiaire de sa chaîne latérale alpha, par réaction du composé de formule (IIIe)



dans laquelle J est un atome d'halogène et R est un groupe alkyle inférieur, avec une thiourée, suivie d'un traitement

avec un acide.


20. Procédé pour la préparation d'un éther phénolique d'acide aminé de formule (I)




de ses formes tautomères, de ses stéréoisomères, de ses polymorphes, de ses sels pharmaceutiquement acceptables, de ses solvates pharmaceutiquement acceptables, formule dans laquelle ---- représente une liaison ; Y représente l'oxygène, le soufre ou NR, où R représente l'hydrogène ou un alkyle ; Z représente l'oxygène ou le soufre ; R₁, R₂, R₃ et R₄ peuvent être identiques ou différents et représentent indépendamment l'hydrogène, un halogène, hydroxy, nitro, cyano, formyle, amino, alkyle ou alcoxy ; A représente une liaison ou un cycle aryle, hétérocyclyle ou hétéroaryle substitué ou non substitué ; X représente un acide alpha-aminocarboxylique ou un dérivé de celui-ci dans lequel le groupe amino est carboxylé ou le groupe acide carboxylique est estérifié ou est un amide, X étant lié à A ou Y par l'intermédiaire de sa chaîne latérale alpha, par réaction d'un composé de formule (III f)




dans laquelle L est un groupe partant nucléophile, avec un composé de formule (III g)




21. Procédé pour la préparation d'un éther phénolique d'acide aminé de formule (I)




de ses formes tautomères, de ses stéréoisomères, de ses polymorphes, de ses sels pharmaceutiquement acceptables, de ses solvates pharmaceutiquement acceptables, formule dans laquelle ---- représente une liaison ; Y représente l'oxygène, le soufre ou NR, où R représente l'hydrogène ou un alkyle ; Z représente l'oxygène ou le soufre ; R₁, R₂, R₃ et R₄ peuvent être identiques ou différents et représentent indépendamment l'hydrogène, un halogène, hydroxy, nitro, cyano, formyle, amino, alkyle ou alcoxy ; A représente une liaison ou un cycle aryle, hétérocyclyle ou hétéroaryle substitué ou non substitué ; X représente un acide alpha-aminocarboxylique ou un dérivé de celui-ci dans lequel le groupe amino est carboxylé ou le groupe acide carboxylique est estérifié ou est un amide, X étant lié à A ou Y par l'intermédiaire de sa chaîne latérale alpha, par réaction d'un composé de formule (III h)



dans laquelle A et X sont tels que définis ci-dessus, avec un composé de formule (IIIg)




10 22. Procédé pour la préparation d'un composé de formule (I)



20 où "----" représente une absence de liaison, par réduction de composés de formule (I) dans lesquels "----" représente une liaison et tous les autres symboles sont tels que définis dans la revendication 1.

25 23. Composition pharmaceutique qui comprend une quantité pharmaceutiquement efficace d'un éther phénolique d'acide aminé de formule (I)



35 tel que défini dans la revendication 1 et un véhicule, diluant, excipient ou solvate pharmaceutiquement acceptable.

24. Composé de formule (I) selon la revendication 1 pour une utilisation dans la réduction du glucose plasmatique.

40 25. Composé de formule (I) selon la revendication 1 pour une utilisation dans la réduction des acides gras libres plasmatiques.

26. Composé de formule (I) selon la revendication 1 pour une utilisation dans la réduction du cholestérol plasmatique.

45 27. Composé de formule (I) selon la revendication 1 pour une utilisation dans la réduction des taux plasmatiques de triglycérides.

28. Composé de formule (I) selon la revendication 1 pour une utilisation dans le traitement de l'obésité.

50 29. Composé de formule (I) selon la revendication 1 pour une utilisation dans le traitement de maladies auto-immunes.

30. Composé de formule (I) selon la revendication 1 pour une utilisation dans le traitement d'une inflammation.

31. Composé de formule (I) selon la revendication 1 pour une utilisation dans le traitement d'une maladie immunologique.

55 32. Composé pour une utilisation selon la revendication 29, dans lequel la maladie auto-immune est la sclérose en plaques.

33. Composé pour une utilisation selon la revendication 29, dans lequel la maladie auto-immune est la polyarthrite


rhumatoïde.

34. Composé pour une utilisation selon la revendication 30, dans lequel l'inflammation est à médiation par une cyclooxygénase.

35. Composé pour une utilisation selon la revendication 31, dans lequel la maladie immunologique est à médiation par des cytokines.


36. Composé de formule (I) selon la revendication 1 pour une utilisation dans le traitement d'un trouble associé à une résistance à l'insuline.

37. Intermédiaire de formule (IIIc)



ses formes tautomères, ses stéréoisomères, ses polymorphes, ses sels pharmaceutiquement acceptables, ses solvates pharmaceutiquement acceptables, formule dans laquelle Y représente l'oxygène, le soufre ou NR, où R représente l'hydrogène ou un alkyle ; R_1 , R_2 , R_3 et R_4 peuvent être identiques ou différents et représentent indépendamment l'hydrogène, un halogène, hydroxy, nitro, cyano, formyle, amino, alkyle ou alcoxy ; A représente un aryle substitué ou non substitué ; X représente un acide alpha-aminocarboxylique ou un dérivé de celui-ci dans lequel le groupe amino est carboxylé ou le groupe acide carboxylique est estérifié ou est un amide, X étant lié à A ou Y par l'intermédiaire de sa chaîne latérale alpha.

38. Intermédiaire de formule (IIIe)



ses formes tautomères, ses stéréoisomères, ses polymorphes, ses sels pharmaceutiquement acceptables, ses solvates pharmaceutiquement acceptables, formule dans laquelle Y représente l'oxygène, le soufre ou NR, où R représente l'hydrogène ou un alkyle ; R_1 , R_2 , R_3 et R_4 peuvent être identiques ou différents et représentent indépendamment l'hydrogène, un halogène, hydroxy, nitro, cyano, formyle, amino, alkyle ou alcoxy ; A représente un aryle substitué ou non substitué ; X représente un acide alpha-aminocarboxylique ou un dérivé de celui-ci dans lequel le groupe amino est carboxylé ou le groupe acide carboxylique est estérifié ou est un amide, X étant lié à A ou Y par l'intermédiaire de sa chaîne latérale alpha ; J représente un atome d'halogène et R_5 représente un groupe alkyle inférieur.

39. Composé selon la revendication 1, dans lequel ledit sel pharmaceutiquement acceptable est choisi parmi les sels chlorhydrates, bromhydrates, de sodium, de potassium et de magnésium.

Inhibition of Pro-Inflammatory Cytokines in THP-1 Cells




FIG. 1

Inhibition of Carrageenan induced PAW edema

SD rat Male (6-7 weeks age)
Average weight 250 g

SD rat Male (6-7 weeks age)
Average weight 250 g

Dexamethasone as positive control, 5mg/kg
Measured hind paw volumes using plethysmometer




FIG. 2

Randomized 15 rats in three groups, route oral, volume 2ml/kg, does 50 mg/kg
30 minutes later carrageenan was administered in the sub-planter region of right hind paw
Paw volume was measured after 2 and 3 hours
Collected blood samples at 0.2 and 3 hours for cytokine profile

Prevention of EAE in SJL/J Mice

Experimental Allergic Encephalomyelitis

- EAE is a model of Multiple Sclerosis
- Clinically & Pathologically similar to human MS
- EAE is induced by SCH or MBP
- Can be induced by reactive CD4⁺ve T cells
- Shows typical Th 1 type cytokine profile
- Clinical score is the level of paralysis
- Shows Relapse-Remitting like human MS

Clinical Scoring Grades:

- Grade 1: Tail paralysis
- Grade 2: Hind limb weak and inability to right
- Grade 3: Paralysis of hind limb
- Grade 4: Paralysis of fore limbs
- Grade 5: Death




FIG. 3

Cytokine modulation in Macrophage & Immune Disorders




FIG. 4




FIG. 5

Hypoglycemic activity of Compound 2 in ob/ob and db/db mice





FIG. 6

Inhibition of body weight gain increase in obese mice models



Inhibition of body weight gain remain effective even after withdrawn of treatment

FIG. 7

Compound 2 lowers serum insulin, TG and cholesterol in ob/ob Mice




FIG. 8

Compound	conc.	OD 1	OD 2	OD 3	Average OD	SD	Corrected Aver. OD	Fold ind.
PreAd		0.091	0.074	0.078	0.081	0.009	-0.014	
Compound 2	0.01 μ M	0.141	0.125	0.123	0.130	0.010	0.035	0.80
	0.1 μ M	0.129	0.134	0.130	0.131	0.003	0.036	0.83
	1 μ M	0.130	0.122	0.117	0.123	0.007	0.028	0.65
	10 μ M	0.120	0.123	0.126	0.123	0.003	0.028	0.65
Rosiglitazone	0.01 μ M	0.134	0.128	0.127	0.130	0.004	0.035	0.80
	0.1 μ M	0.148	0.155	0.170	0.158	0.011	0.063	1.45
	1 μ M	0.243	0.267	0.235	0.248	0.017	0.153	3.54
	10 μ M	0.290	0.275	0.311	0.292	0.018	0.197	4.55
BRL + TNFa	1 μ M	0.162	0.151	0.139	0.151	0.012	0.056	1.28
Vehicle		0.130	0.129	0.156	0.138	0.015	0.043	
Blank		0.108	0.089	0.088	0.095	0.011	0.000	

Oil Red O




FIG. 9

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 5441971 A [0012]

Non-patent literature cited in the description

- | | |
|---|---|
| • Moser et al. <i>J Clin Invest</i> , 1989, vol. 83, 444-55 [0003] | • Amos A. ; McCarty, D. ; Zimmet, P. <i>Diabetic Med.</i> , 1997, vol. 14, S1-S85 [0010] |
| • Haworth et al. <i>Eur J Immunol</i> , 1991, vol. 21, 2575-79 [0003] | • King, H. ; Aubert, R. ; Herman, W. <i>Diabetes Care</i> , 1998, vol. 21, 1414-1431 [0010] |
| • Brennan et al. <i>Lancet</i> , 1989, vol. 2, 244-7 [0003] | • Moller, D.E. <i>Nature</i> , 2001, vol. 414, 821-827 [0010] |
| • Arend et al. <i>Arthritis Rheum</i> , 1995, vol. 38, 151-60 [0003] | • Amos, A. ; McCarty, D. ; Zimmet, P. <i>Diabetic Med.</i> , 1997, vol. 14, S1-S85 [0010] |
| • Goldenberg. <i>Clin Ther</i> , 1999, vol. 21, 75-87 [0003] | • Kopelman, P.G. ; Hitaman, G.A. <i>Lancet</i> , 1998, vol. 352, SIV5 [0010] |
| • Luong et al. <i>Ann Pharmacother</i> , 2000, vol. 34, 743-60 [0003] | |